[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1758
1. Nunnari G, Smith JA, Daniel R: HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res; 2008 May 15;27:3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier?
  • The acquired immunodeficiency syndrome (AIDS) is accompanied by a significant increase in the incidence of neoplasms.
  • Cancer in general is closely linked to genomic instability and DNA repair mechanisms.
  • The latter maintains genomic stability and serves as a cellular anti-cancer barrier.
  • Defects in DNA repair pathway are associated with carcinogenesis.
  • We propose that the Tat-induced DNA repair deficiencies may play a significant role in the development of AIDS-associated cancer.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Apr 22;308(5721):551-4 [15790808.001]
  • [Cites] Cell Cycle. 2005 Mar;4(3):359-62 [15684609.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2634-45 [16001085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13182-7 [16141325.001]
  • [Cites] Front Biosci. 2006;11:1958-76 [16368571.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):91-9 [16341205.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):297-303 [16461339.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):842-50 [16751065.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):827-39 [17189186.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):993-1002 [16909103.001]
  • [Cites] Curr HIV Res. 2007 Jul;5(4):403-9 [17627503.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1063-7 [17728759.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5613-7 [8516308.001]
  • [Cites] Am J Gastroenterol. 1994 Feb;89(2):254-6 [8304313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6904-8 [8041718.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Virology. 1996 Feb 15;216(2):357-66 [8607265.001]
  • [Cites] Cell. 1996 Aug 9;86(3):379-89 [8756720.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1425-33 [9032269.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):84-93 [9207353.001]
  • [Cites] Nature. 1997 Jul 31;388(6641):492-5 [9242410.001]
  • [Cites] Curr Biol. 1997 Aug 1;7(8):588-98 [9259561.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1623-8 [9430704.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):969-79 [9651580.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5497-508 [9736627.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6412-25 [9799249.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3299-304 [10866324.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95 [10959836.001]
  • [Cites] Cell. 2000 Aug 18;102(4):463-73 [10966108.001]
  • [Cites] Adv Pharmacol. 2000;48:209-27 [10987092.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1162-6 [10550055.001]
  • [Cites] Mutat Res. 1973 Oct;20(1):45-51 [4586554.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):616-9 [3390798.001]
  • [Cites] Am J Clin Pathol. 1989 Apr;91(4):458-61 [2929501.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] EMBO J. 2000 Apr 3;19(7):1703-10 [10747037.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):613-7 [10766245.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):897-900 [10786799.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):677-9 [10793096.001]
  • [Cites] Nat Genet. 2000 May;25(1):115-9 [10802669.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3772-80 [10805721.001]
  • [Cites] Nature. 2000 May 25;405(6785):473-7 [10839544.001]
  • [Cites] Nature. 2000 May 25;405(6785):477-82 [10839545.001]
  • [Cites] Adv Pharmacol. 2000;48:229-50 [10987093.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):433-9 [11100718.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):2989-3002 [11114888.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):71-7 [11163154.001]
  • [Cites] AIDS. 2001 Mar 9;15(4):433-40 [11242139.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):544-56 [11549560.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1713-6 [11721054.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47759-62 [11673449.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):19-24 [11836442.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1704-12 [11927554.001]
  • [Cites] Nat Cell Biol. 2002 Dec;4(12):993-7 [12447390.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):497-501 [12640452.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] Science. 2003 Jun 6;300(5625):1542-8 [12791985.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Am Surg. 2003 Nov;69(11):981-7 [14627261.001]
  • [Cites] Acta Biochim Pol. 2003;50(4):891-908 [14739985.001]
  • [Cites] Nature. 2004 Mar 25;428(6981):431-7 [15042092.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2664-71 [14755242.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2347-60 [15020715.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):11-6 [15108799.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):147-54 [15196461.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):509-14 [15254414.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S42-51 [9806608.001]
  • [Cites] Cell. 1998 Nov 25;95(5):583-6 [9845359.001]
  • [Cites] Cell. 1998 Nov 25;95(5):705-16 [9845372.001]
  • [Cites] Genes Cells. 1998 Dec;3(12):789-800 [10096020.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1276-88 [10346816.001]
  • [Cites] Biochemistry. 1999 Jul 6;38(27):8826-30 [10393559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8324-6 [10411869.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1453-8 [10469745.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):905-16 [10477747.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4375-82 [10485486.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):715-24 [15574327.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):123-32 [15603757.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2084-7 [15528408.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):949-61 [15592499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1877-82 [15671175.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2433; author reply 2433-4 [15800341.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):605-11 [15758953.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • (PMID = 18577246.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA098090; United States / NCI NIH HHS / CA / R01 CA125272; United States / NCI NIH HHS / CA / CA125272; United States / NCI NIH HHS / CA / CA98090
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 99
  • [Other-IDs] NLM/ PMC2438332
  •  go-up   go-down


2. Hunt PW: Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS; 2010 Mar;5(2):189-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Although the vast majority of HIV-infected individuals can now achieve and maintain viral suppression with modern-antiretroviral therapy (ART), their life expectancy remains much shorter than the general population and they continue to be at much higher risk for non-AIDS-associated diseases commonly associated with aging (non-AIDS-associated cancer, cardiovascular disease, etc).
  • Although the causes of persistent-immune activation remain incompletely characterized, persistent low-level HIV replication and/or release from latently infected cells in gut-associated lymphoid tissue (GALT) and microbial translocation probably play a major role.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2737-45 [11762933.001]
  • [Cites] J Infect Dis. 2003 May 15;187(10):1534-43 [12721933.001]
  • [Cites] J Virol. 2003 Nov;77(21):11708-17 [14557656.001]
  • [Cites] N Engl J Med. 2003 Dec 18;349(25):2407-15 [14681506.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):520-8 [14762789.001]
  • [Cites] AIDS. 2004 Jan 1;18 Suppl 1:S79-86 [15075502.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3482-91 [15322213.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):761-70 [15365095.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] Immunity. 2004 Oct;21(4):467-76 [15485625.001]
  • [Cites] Ann Rheum Dis. 1995 Apr;54(4):274-6 [7763104.001]
  • [Cites] Arthritis Care Res. 1995 Sep;8(3):137-45 [7654797.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Science. 1998 Apr 17;280(5362):427-31 [9545219.001]
  • [Cites] J Rheumatol. 1998 Jul;25(7):1282-9 [9676757.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1310-6 [16670770.001]
  • [Cites] J Infect Dis. 2006 Jul 1;194(1):29-37 [16741879.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34 [16810109.001]
  • [Cites] J Exp Med. 2006 Oct 2;203(10):2271-9 [16982811.001]
  • [Cites] Nat Med. 2006 Dec;12(12):1365-71 [17115046.001]
  • [Cites] Ann Intern Med. 2007 Jan 16;146(2):87-95 [17227932.001]
  • [Cites] AIDS. 2007 Mar 30;21(6):685-92 [17413689.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12 [17456578.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7 [17621240.001]
  • [Cites] J Infect Dis. 2008 Feb 1;197(3):420-9 [18199035.001]
  • [Cites] J Clin Microbiol. 2008 Feb;46(2):757-8 [18094140.001]
  • [Cites] Nat Med. 2008 Apr;14(4):421-8 [18376406.001]
  • [Cites] J Infect Dis. 2008 Apr 15;197(8):1133-44 [18476292.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] JAMA. 2008 Jul 2;300(1):51-9 [18594040.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):339-54 [18650512.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):590-8 [18645512.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3499-504 [18593764.001]
  • [Cites] AIDS. 2008 Oct 1;22(15):2035-8 [18784466.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2826-35 [18664624.001]
  • [Cites] N Engl J Med. 2008 Oct 2;359(14):1429-41 [18832244.001]
  • [Cites] Clin Infect Dis. 2008 Nov 15;47(10):1345-53 [18834317.001]
  • [Cites] PLoS Med. 2008 Oct 21;5(10):e203 [18942885.001]
  • [Cites] BMJ. 2009;338:a3172 [19171560.001]
  • [Cites] PLoS Pathog. 2009 Feb;5(2):e1000295 [19214220.001]
  • [Cites] J Infect Dis. 2009 Apr 15;199(8):1177-85 [19265479.001]
  • [Cites] Lancet. 2009 Apr 18;373(9672):1352-63 [19361855.001]
  • [Cites] Top HIV Med. 2009 Apr-May;17(2):46-56 [19401607.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1815-26 [19339714.001]
  • [Cites] J Infect Dis. 2009 Oct 15;200(8):1212-5 [19728788.001]
  • [Cites] Blood. 2010 Jan 14;115(2):161-7 [19828697.001]
  • [Cites] AIDS. 2002 Sep 27;16(14):1859-66 [12351945.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):506-12 [12869840.001]
  • (PMID = 20543599.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K23 AI065244; United States / NIAID NIH HHS / AI / K23 AI065244-05
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Number-of-references] 52
  • [Other-IDs] NLM/ NIHMS203435; NLM/ PMC2917631
  •  go-up   go-down


3. Sampaio J, Brites C, Araujo I, Bacchi CE, Dittmer DP, Tanaka PY, Harrington W Jr, Netto EM: AIDS related malignancies in Brazil. Curr Opin Oncol; 2007 Sep;19(5):476-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related malignancies in Brazil.
  • PURPOSE OF REVIEW: There have been relatively few studies of HIV-related malignancies in Brazil.
  • Universal access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS.
  • Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system.
  • This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
  • In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US.
  • SUMMARY: The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2005 Oct;19 Suppl 4:S27-30 [16249650.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S133-4 [16619688.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):719-23 [16628586.001]
  • [Cites] Braz J Med Biol Res. 2006 May;39(5):573-80 [16648893.001]
  • [Cites] Int J Hematol. 2006 Nov;84(4):337-42 [17118760.001]
  • [Cites] Pathol Res Pract. 2007;203(1):1-7 [17157997.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):643-7 [15357742.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):619-23 [15468433.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63 [8315579.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1488-91 [9780272.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Int J Infect Dis. 2005 Sep;9(5):239-50 [16095940.001]
  • (PMID = 17762574.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / CA109232-04; United States / FIC NIH HHS / TW / 5D43 TW00017-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS191349; NLM/ PMC2855639
  •  go-up   go-down


Advertisement
4. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.
  • SUMMARY: The burden of neoplastic complications of HIV infection and endemic virus-associated tumors are assuming increasing significance in Africa.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


5. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst; 2007 Jun 20;99(12):962-72
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.
  • BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.
  • We investigated the association between cancer risk and CD4 cell count among such persons.
  • METHODS: Data from US AIDS registries were linked to local cancer registry data.
  • Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.
  • The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.
  • RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).
  • Cervical cancer incidence was higher in 1996-2002 (86.5 per 100,000 person-years) than in 1990-1995 (64.2 per 100,000 person-years), although not statistically significantly so (relative risk [RR] = 1.41, 95% CI = 0.81 to 2.46).
  • Similar relationships of these cancers to CD4 count were observed for 1990-1995.
  • CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.
  • The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565153.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


6. Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist; 2005 Jun-Jul;10(6):412-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
  • Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).
  • Despite the advent of highly active anti-retroviral therapy (HAART), malignancy in this population is a leading cause of morbidity and mortality.
  • Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.
  • AIDS-related KS varies from minimal to fulminant disease.
  • Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.
  • Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.
  • ARL comprises a heterogeneous group of malignancies.
  • HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.
  • Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.
  • This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy


7. Noguchi K, Fukazawa H, Murakami Y, Takahashi N, Yamagoe S, Uehara Y: Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci; 2007 Sep;98(9):1288-96
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies.
  • gamma-Herpesviruses, Epstein-Barr virus (EBV/HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), are involved in human carcinogenesis, particularly in immunocompromised patients.
  • Virus-associated malignancies are becoming of significant concern for the mortality of long-lived immunocompromised patients, and therefore, research of advanced strategies for AIDS-related malignancies is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV and KSHV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy.
  • The present review gives a simple outline of the functional interactions between KSHV- and EBV-viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS-related malignancies.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / metabolism. Sarcoma, Kaposi / virology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640300.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


8. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


9. Chaturvedi AK, Mbulaiteye SM, Engels EA: Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol; 2008 Mar;18(3):230-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers.
  • PURPOSE: Registry-based studies provide valuable data regarding cancer risk among people with HIV/AIDS (PWHA).
  • However, SIR may underestimate RR when HIV/AIDS prevalence in the general population or RR is high.
  • We quantified the extent of this underestimation for 3 AIDS-related cancers: Kaposi sarcoma (KS), central nervous system non-Hodgkin lymphoma (CNS NHL) and cervical cancer.
  • METHODS: We used data on cancer risk among PWHA from the U.S.
  • HIV/AIDS Cancer Match Study.
  • (1) SIRs calculated using pre-AIDS era (1973-1979) cancer incidence rates (SIRpre-AIDS) and (2) SIRs calculated after subtraction of cancers known to be among PWHA from general population rates (SIRexclusion).
  • RESULTS: For KS and CNS NHL, SIRs (117.8 and 133.9, respectively) calculated using overall general population rates substantially underestimated both SIRpre-AIDS (19,778 and 3,612, respectively) and SIRexclusion (657.7 and 536.4, respectively).
  • In contrast, the extent of underestimation was negligible for cervical cancer (SIR = 4.9 vs. SIRexclusion = 5.1).
  • However, SIRpre-AIDS and SIRexclusion estimates were more similar, indicating that SIR differences artifactually reflect differences in HIV/AIDS prevalence between males and females.
  • For KS and CNS NHL, trends across calendar time were weaker in SIRs than in SIRpre-AIDS and SIRexclusion.
  • SIRs must be interpreted cautiously when HIV/AIDS prevalence is high or varies across groups of interest.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / epidemiology


10. Warley E, Tamayo Antabak N, Desse J, De Luca A, Warley F, Fernández Galimberti G, D'Agostino G, Quintas L, Szyld E: [Development of AIDS-related malignancies and infections after starting HAART]. Medicina (B Aires); 2010;70(1):49-52
Hazardous Substances Data Bank. AZITHROMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of AIDS-related malignancies and infections after starting HAART].
  • In order to evaluate the incidence rate and possible risk factors associated with AIDS-related malignancies and infections (ARMI) we performed data analysis of clinical charts of HIV patients in two hospital cohorts, that started high activity antiretroviral therapy (HAART) between July 2003 and October 2007.
  • A CD4 cell count < 100/150 was associated with risk of developing ARMI.
  • TB in first place and cryptococcosis in second were the AIDS events more frequently observed.
  • A low CD4 cell count was the only observed risk factor statistically associated with development of ARMI.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology


11. D'Olimpio JT, Chasen MR, Sharma R, Diego M, Gullo V, MacDonald N: Phase II study of AVR118 in the management of cancer related anorexia/cachexia. J Clin Oncol; 2009 May 20;27(15_suppl):e20631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of AVR118 in the management of cancer related anorexia/cachexia.
  • : e20631 Background: AVR118 represents a new class of cytoprotective drugs in managing symptoms associated with anorexia\/ cachexia.
  • In a previous study in patients with advanced HIV-AIDS, an improvement in appetite, strength and alertness was noted.
  • The precise mechanism of action is not understood, but activity may be related to AVR118's adenosine based components.
  • OBJECTIVE: To determine the effect of AVR118 on appetite, early satiety and nutritional intake in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Williams CK: HIV/AIDS pandemic (AP) in Africa: Chronicle of a missed opportunity. J Clin Oncol; 2009 May 20;27(15_suppl):e22235

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV/AIDS pandemic (AP) in Africa: Chronicle of a missed opportunity.
  • : e22235 Background: AP unlike HTLV-I associated diseases arrived late in parts of Africa, including Nigeria, where retroviral research was already ongoing in collaboration with the US National Cancer Institute (USNCI), thus providing unique preventive interventional opportunity.
  • Assuming 20 HIV-1+ = 1 case of AIDS death, SWB- determined SPR predicted (∼12-24)×10<sup>3</sup> AIDS deaths among 48×10<sup>6</sup> AGNP in 1985-86, ∼5 of (2.4- 4.8)×10<sup>3</sup> (<0.2%) of whom presented with clinical AIDS features (CAF) at Nigeria's premier health institution (NPHI).
  • Reports of SPR of 7.7 and 60.0 in AGNP and FCSW in 1996-2000 contrast against contemporary Ugandan SPR (14.0 down to 6.1) and Senegalese (0.4 up to 0.9), probably resulting from varying knowledge gap and angst-related inertia, illustrating mixed fortunes of AP in Africa, transcontinental variation in AP control capability, and providing lessons for the management of future public health challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gercovich FG, Gil Deza E, Martin Reina G, Garcia Gerardi C, Abal M, Santillan D, Tognelli F, Calarame J, Rivarola E, Morgenfeld E: 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real? J Clin Oncol; 2009 May 20;27(15_suppl):e17535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?
  • : e17535 Background: Juvenile Cancer (JC) involves patients between 18 and 29 years old (adult pt less than 30 yo) and can be or not associated to AIDS.
  • The non-AIDS JC pt challenge the clinical oncologist in many ways: there are few preventive measures, avoiding delayed toxicities is mandatory (fertility, cognitive impairment) and there is a lack of evidence-based treatments for uncommon tumors.
  • The aim of this paper is to evaluate the incidence and clinical outcome of JC non AIDS related at the IOHM.
  • The inclusion criteria was: new cancer pt diagnosed between 18 and 29 yo.
  • DIAGNOSIS: Expected tumors 269 pt (80%) (testicular tumors = 89 pt; lymphoma = 75 pt; sarcoma = 35 pt; melanoma = 17 pt; others = 53), Unexpected tumors 67 pt (20%) (gastrointestinal = 23 pt; breast cancer = 17 pt; ovarian = 13 pt; head and neck = 7 pt; others = 7 pt).
  • 1) In our database, 336 cases of JC out of 12.828 new cancer patients between were found 2001 and 2008;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cuéllar Ponce de León LE Sr, Miranda Rosales LM Sr, Biminchumo Zagástegui C, Rosales Cusichaqui R, Flores C Sr, Mas López L Sr, León Chong J Sr: Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e20550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus/acquired immunodeficiency syndrome-related cancer in the pre- and post-highly active antiretroviral therapy era in a national cancer center of a resource-limited country: 1988 to 2007.
  • : e20550 Background: The introduction of the highly active antiretroviral therapy (HAART) has changed the clinical course of acquired immune deficiency syndrome (AIDS) related to cancer.
  • The goals were to describe the the characteristics of AIDS related to cancer before and after HAART in patients in a Hospital of a resource-limited country.
  • The number of invasive cervical cancer (CC) and AIDS-related lymphomas (ARLs) increased in the Post HAART era; the number on non-HIV/AIDS related to cancer has decreased.
  • CONCLUSIONS: The introduction of HAART has reduced the number of non-VIH/AIDS related cancer, but have increased the CC and LNH and improved the survival of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


16. Phatak UA, Joshi R, Badakh DK, Gosavi VS, Phatak JU, Jagdale RV: AIDS-associated cancers: an emerging challenge. J Assoc Physicians India; 2010 Mar;58:159-62
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated cancers: an emerging challenge.
  • OBJECTIVES: To study the incidence and effects of anti-retroviral therapy along with cancer chemotherapy on outcome of AIDS associated Cancers in Indian patients.
  • METHOD: 3832 cancers patients were investigated over a period of 5 years.
  • 46 AIDS-associated cancers were identified.
  • Patients were treated with different modalities of cancer management and anti-retroviral therapy was discussed with the patient and relatives.
  • RESULTS: Incidence of AIDS-associated cancers was 1.2 percent.
  • AIDS-Defining Cancers (ADC) were seen in 26 (54.35%) while non-AIDS-Defining Cancers (NADC) were observed in 21 (45.65%).
  • Non Hodgkin Lymphoma was the commonest form of AIDS-defining cancers in 21 (84%) patients, cervical cancers in 4 (16%) women while there was not a single case of Kaposi's Sarcoma.
  • AIDS associated cancers were common in males.
  • Only 33.5% patients received treatment for HIV and cancers.
  • CONCLUSIONS: AIDS-associated cancers are seen in advanced stage of HIV infection.
  • Cervical cancers and non-AIDS-defining cancers do not show predictable response to anti-retroviral therapy.
  • Mortality in non-AIDS related cancers was significantly higher than AIDS related cancers.


17. Shackelford J, Pagano JS: Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem; 2007;8 Suppl 1:S8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
  • Tumor viruses are linked to approximately 20% of human malignancies worldwide.
  • This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.
  • The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.
  • We discuss the molecular mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-cancer therapy from the perspective of this system.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]
  • [Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]
  • [Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • [Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Ann Med. 2003;35(6):404-12 [14572164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]
  • [Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]
  • [Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]
  • [Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]
  • [Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]
  • [Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]
  • [Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]
  • [Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]
  • [Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]
  • (PMID = 18047745.001).
  • [ISSN] 1471-2091
  • [Journal-full-title] BMC biochemistry
  • [ISO-abbreviation] BMC Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2106372
  •  go-up   go-down


18. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'dom P, Malvy D, Dabis F: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One; 2010;5(1):e8621
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of AIDS-related malignancies in sub-Saharan Africa.
  • BACKGROUND: With the lengthening of life expectancy among HIV-positive subjects related to the use of highly active antiretroviral treatments, an increased risk of cancer has been described in industrialized countries.
  • The objective of our paper is to review the link between HIV and cancer in sub-Saharan Africa, putting it in perspective with what is already known in Western countries.
  • METHODS AND FINDINGS: Studies for this review were identified from several bibliographical databases including Pubmed, Scopus, Cochrane, Pascal, Web of Science and using keywords "HIV, neoplasia, epidemiology and Africa" and related MesH terms.
  • A clear association was found between HIV infection and AIDS-classifying cancers.
  • The association was less strong for invasive cervical cancer with ORs ranging from 1.1 (0.7-1.2) to 1.6 (1.1-2.3), whereas ORs for squamous intraepithelial lesions were higher, from 4.4 (2.3-8.4) to 17.0 (2.2-134.1).
  • For non AIDS-classifying cancers, squamous cell conjunctival carcinoma of the eye was associated with HIV in many case-referent studies with ORs from 2.6 (1.4-4.9) to 13.0 (4.5-39.4).
  • Other cancer sites found positively associated with HIV include lung, liver, anus, penis, vulva, kidney, thyroid and uterus and a decreased risk of female breast cancer.
  • CONCLUSION: Studies conducted in sub-Saharan Africa show that HIV infection is not only strongly associated with AIDS-classifying cancers but also provided some evidence of association for other neoplasia.
  • African countries need now to implement well designed population-based studies in order to better describe the spectrum of AIDS-associated malignancies and the most effective strategies for their prevention, screening and treatment.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S121-4 [8547501.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):587-91 [8774574.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):308-14 [8804445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):37-42 [9709301.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Int J Gynaecol Obstet. 1999 May;65(2):171-81 [10405062.001]
  • [Cites] Sex Transm Infect. 1999 Apr;75(2):103-6 [10448362.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):659-61 [11295098.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):194-7 [11437924.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jan;76(1):55-63 [11818095.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Womens Health (Larchmt). 2003 Apr;12(3):227-32 [12804353.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76 [15778115.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):914-9 [16565210.001]
  • [Cites] BMC Cancer. 2006;6:135 [16719902.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):1-7 [16542773.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9 [17403438.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(4):222-8 [17191009.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2260-5 [18241034.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] J Med Virol. 2008 May;80(5):847-55 [18360898.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Lancet. 2008 May 3;371(9623):1504 [18456099.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):301-5 [10918766.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2401-8 [9635533.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Int J STD AIDS. 2003 Oct;14(10):647-51 [14596765.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1982 May 1;1(8279):1026-7 [6122840.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Lancet. 1990 Jul 7;336(8706):51-2 [1973230.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):309-11 [1637026.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):29-36 [7558448.001]
  • (PMID = 20066157.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2799672
  •  go-up   go-down


19. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


20. Yarchoan R, Tosato G, Little RF: Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol; 2005 Aug;2(8):406-15; quiz 423
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
  • Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas.
  • Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein-Barr virus.
  • The development of highly active antiretroviral therapy (HAART) has reduced the incidence of many HIV-associated tumors and has generally improved their responsiveness to therapy.
  • However, the number of people living with AIDS is increasing, and it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors will change as more people live longer with HIV infection.
  • By contrast, the goal of AIDS-related lymphoma therapy in most cases is the attainment of a complete response with curative intent, and the benefits of administering HAART during therapy must be weighed against possible disadvantages.
  • The past decade has seen substantial improvements in the treatment of AIDS-related lymphoma, which is attributed partially to a shift in tumor type and more effective regimens.
  • There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / virology


21. Neuman HB, Charlson ME, Temple LK: Is there a role for decision aids in cancer-related decisions? Crit Rev Oncol Hematol; 2007 Jun;62(3):240-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for decision aids in cancer-related decisions?
  • Cancer-related decisions are challenging, requiring patients to evaluate associated medical and psychological outcomes within the context of their personal values.
  • Clinical decision aids are decisional support tools designed to facilitate patient-driven decision-making by providing relevant information on the options while eliciting and incorporating patient preferences; they have been designed to support decision-making in the prevention, screening, and treatment of cancer.
  • In randomized controlled trials, cancer-related decision aids have been shown to increase patients' knowledge regarding their disease, and may facilitate patients playing a more active role in decision-making.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317206.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


22. Schlichemeyer R, Chambers C, Gill MJ: The oncology impact of highly active antiretroviral therapy. J Oncol Pharm Pract; 2007 Mar;13(1):17-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers.
  • METHODS: We used the Southern Alberta Clinic (SAC) database to define the incidence and prevalence of AIDS-related cancers in a geographically defined HIV population in both the pre- HAART and HAART eras, and subsequently, the Alberta Cancer Board Pharmacy database to determine the chemotherapy associated costs of the cancer treatment.
  • RESULTS: During both eras, 60% of AIDS-related cancer patients received chemotherapy.
  • The absolute number of patients treated in the pre-HAART era was 70, but during the HAART era, due to the decreased incidence of these cancers, only 13 patients received chemotherapy.
  • The number of distinct regimens used for AIDS cancer treatment standardised, and decreased from 29 to six between eras.
  • CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621563.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Immun Ageing. 2008 Sep 24;5:11 [18816370.001]
  • [Cites] Arch Intern Med. 2009 Jun 22;169(12):1130-8 [19546414.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):7-10 [19532075.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1965-71 [18675102.001]
  • [Cites] AIDS. 2009 May 15;23(8):875-85 [19349851.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] Clin Infect Dis. 2009 Oct 1;49(7):1109-16 [19705973.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 [19412116.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):432-7 [17307327.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS Educ Prev. 2009 Jun;21(3 Suppl):3-13 [19537950.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2326-32; discussion 2332 [19029496.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Curr Infect Dis Rep. 2009 Sep;11(5):407-13 [19698285.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2058-9 [17917974.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):345-50 [19135758.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lou J, Ruggeri T, Tebaldi C: Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior. Math Biosci Eng; 2006 Apr;3(2):313-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior.
  • For HIV-infected individuals, cancer remains a significant burden.
  • Gaining insight into the epidemiology and mechanisms that underlie AIDS- related cancers can provide us with a better understanding of cancer immunity and viral oncogenesis.
  • In this paper, an HIV-1 dynamical model incorporat- ing the AIDS-related cancer cells was studied.
  • The model consists of three components, cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes, and can have six steady states.
  • We discuss the existence, the stability properties and the biological meanings of these steady states, in par- ticular for the positive one: cancer-HIV-healthy cells steady state.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361826.001).
  • [ISSN] 1547-1063
  • [Journal-full-title] Mathematical biosciences and engineering : MBE
  • [ISO-abbreviation] Math Biosci Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • This is mostly explained by the paucity of supportive care compounded by wasting and inanition attributable to advanced cancer and HIV infection making patients more susceptible to myelosuppressive side effects of cytotoxic chemotherapy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • Implementation of these investigational approaches must be encouraged as viable anti-cancer therapeutic strategies particularly in the resource-constrained settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


26. Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M: Use of antidepressants and risk of cancer in individuals infected with HIV. J Clin Oncol; 2008 May 10;26(14):2305-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of antidepressants and risk of cancer in individuals infected with HIV.
  • PURPOSE: Preclinical and cohort studies suggest that certain antidepressants are associated with a predisposition to cancer whereas others decrease the risk.
  • We aimed to assess whether different classes of antidepressants were associated with changes in cancer incidence in a population of HIV-1 infected individuals, based on duration of exposure.
  • METHODS: Antidepressant exposure was measured from date of first prescription of the antidepressant until the date of last follow-up or cancer diagnosis.
  • Univariate and multivariate analyses were performed to establish the risk of AIDS-related cancers and non-AIDS-related cancers according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antidepressants, or other medicines for depression.
  • A total of 1,607 (15%) individuals were diagnosed with cancer.
  • There were no significant associations between any class of antidepressant and any type of cancer (P = .19), in either the pre-HAART or HAART era (P = .23), and use of serotonin reuptake inhibitors did not alter the risk of Burkitt lymphoma.
  • CONCLUSION: Antidepressants, irrespective of their class, do not affect cancer risk in HIV-infected individuals.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467722.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antidepressive Agents, Tricyclic; 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


27. Tserenpuntsag B, Kołacińska A, Jabłonowska E: [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)]. Przegl Epidemiol; 2007;61(3):529-34
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
  • [Transliterated title] Nowotwory zwiazane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART).
  • HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency.
  • Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies.
  • It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers.
  • With the immune restoration afforded by HAART, patients better responded to cancer treatment.
  • HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology. Uterine Cervical Neoplasms / virology


28. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses.
  • This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


29. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


30. Deeken JF, Pantanowitz L, Dezube BJ: Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol; 2009 Sep;21(5):445-54
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.
  • PURPOSE OF REVIEW: Highly active antiretroviral therapy has led to a dramatic improvement in the prognosis of patients diagnosed with HIV and AIDS.
  • This includes a significant decline in the rates of AIDS-related cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Unfortunately, rates of non-AIDS-defining cancers are on the rise, and now exceed the rates of AIDS-related cancers in patients with HIV.
  • Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question.
  • RECENT FINDINGS: Newer targeted therapies are now available to treat cancers which were historically refractory to traditional cytotoxic chemotherapy.
  • We conclude with considerations on how to use these new agents to treat non-AIDS-defining cancers, and discuss a future research agenda to better understand and predict potential highly active antiretroviral therapy-targeted therapy interactions.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] J Clin Pharmacol. 2008 Feb;48(2):209-14 [18077730.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37 [18333863.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1797-802 [18458675.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Drug Metab Dispos. 2008 Sep;36(9):1828-39 [18556438.001]
  • [Cites] J Clin Pharmacol. 2008 Sep;48(9):1032-40 [18728241.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408 [18806898.001]
  • [Cites] Top HIV Med. 2008 Oct-Nov;16(4):117-21 [18838745.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Clin Ther. 2008 Nov;30(11):1956-75 [19108785.001]
  • [Cites] Clin Genitourin Cancer. 2009 Jan;7(1):24-7 [19213664.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):579-87 [19101137.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82 [19271026.001]
  • [Cites] Br J Clin Pharmacol. 2009 Apr;67(4):421-6 [19371315.001]
  • [Cites] Clin Pharmacokinet. 2009;48(3):199-209 [19385713.001]
  • [Cites] Drug Metab Dispos. 2009 Jun;37(6):1242-50 [19282395.001]
  • [Cites] Drug Metab Dispos. 1999 Dec;27(12):1488-95 [10570031.001]
  • [Cites] Drug Metab Dispos. 2001 Feb;29(2):100-2 [11159797.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46 [19455266.001]
  • [Cites] Clin Pharmacol Ther. 1990 May;47(5):647-54 [2111751.001]
  • [Cites] Drug Metab Dispos. 1990 May-Jun;18(3):369-72 [1974201.001]
  • [Cites] AIDS. 1992 Dec;6(12):1471-5 [1283519.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Apr;277(1):423-31 [8613951.001]
  • [Cites] Drug Metab Dispos. 1997 Feb;25(2):256-66 [9029057.001]
  • [Cites] J Clin Pharmacol. 1998 Feb;38(2):106-11 [9549640.001]
  • [Cites] Drug Metab Dispos. 1998 Jun;26(6):552-61 [9616191.001]
  • [Cites] J Pharm Sci. 1998 Jul;87(7):803-7 [9649346.001]
  • [Cites] Drug Metab Dispos. 1998 Jul;26(7):609-16 [9660842.001]
  • [Cites] Drug Metab Dispos. 1999 Jan;27(1):86-91 [9884314.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):902-8 [10421617.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Pharmacokinet. 2005;44(2):111-45 [15656694.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Clin Colorectal Cancer. 2005 Sep;5(3):188-96 [16197622.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1723-8 [16103134.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1729-39 [16118329.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85 [16433896.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):685-92 [16133532.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):702-8 [16443666.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8 [16940065.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:27-30 [17159773.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):602-6 [17267620.001]
  • [Cites] Clin Pharmacol Ther. 2002 Jul;72(1):1-9 [12151999.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):135-54 [12399160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4009-16 [12873999.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1855-9 [14612892.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9 [14692719.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40 [15247556.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):290-4 [15138710.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2684-91 [17473200.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Pharmacotherapy. 2007 Jun;27(6):888-909 [17542771.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3731-7 [17575239.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4849-57 [17699864.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1554-63 [17540708.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1657-63 [17591678.001]
  • [Cites] J Clin Pharmacol. 2007 Nov;47(11):1430-9 [17913896.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7394-400 [18094422.001]
  • (PMID = 19606034.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS382143; NLM/ PMC3377583
  •  go-up   go-down


31. Cadogan M, Dalgleish AG: HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv Cancer Res; 2008;101:349-95
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies.
  • Chronic generalized immune activation represents one of the most critical features determining progression to AIDS.
  • This may result in the manifestation of malignancy, with lymphoma and Karposi's sarcoma being the first to be recognised.
  • Despite a lifecycle adapted to the host and possessing a plethora of survival strategies, HIV promotes disease progression in a manner that is consistently associated with the HLA repertoire suggesting pathogenic features relating to immunological incompatibility may be at the root of disease.
  • Here we review the influence of immune activation on progression to AIDS with particular reference to molecular mimicry and autoimmune phenomenon and highlight the therapeutic potential of non-neutralizing antibodies and strategies designed to diffuse immune activation.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. Alleles. Amino Acid Sequence. Animals. Disease Progression. Disease Susceptibility. HLA Antigens / chemistry. Humans. Immune System. Molecular Sequence Data. Sequence Homology, Amino Acid. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055948.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 350
  •  go-up   go-down


32. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


33. Akanmu AS: AIDS-associated malignancies. Afr J Med Med Sci; 2006 Dec;35 Suppl:57-70
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated malignancies.
  • A number of immunodeficiency states--both inherited (such as agammaglobulinaemia, Bloom's syndrome, hereditary telangiectasia) and acquired (e.g. immunosuppressive therapy) have been associated with varieties of cancers.
  • HIV induces more profound immunodeficiency state and it should not be difficult to imaging why cancer diagnosis is made in over 40% of HIV infected patients.
  • Impairment of normal function of natural killer cells as a result of lack of helper signals from CD4+ T-lymphocytes may be a major mechanism of increased susceptibility to cancer development in HIV infected patients.
  • Although many neoplastic diseases could occur at a frequency not higher than would be expected by chance alone, the biological behaviour of such malignancies tend to be more aggressive.
  • Three neoplastic diseases are associated so commonly with HIV infection that each of them has become recognized as an AIDS defining illness.
  • Both KS and NHL were recognized as AIDS associated cancers from the onset of the epidemic in 1981 but carcinoma of the cervix became AIDS defining in 1993.
  • [MeSH-major] HIV. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050776.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 114
  •  go-up   go-down


34. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P, Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group, Mortavic Study Group: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis; 2009 Mar 1;48(5):633-9
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
  • BACKGROUND: The goal of the current study was to describe the distribution and characteristics of malignancy related deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
  • RESULTS: Among the 1042 deaths reported in 2005 (964 were reported in 2000), 344 were cancer related (34%), which represented a significant increase from 2000 (29% of deaths were cancer related) (P=.02); 134 of the cancer-related deaths were AIDS related and 210 were not AIDS related.
  • Among the cancer-related causes of death, the proportion of hepatitis-related cancers (6% in 2000 vs. 11% in 2005) and non-AIDS/hepatitis-related cancers (38% in 2000 vs 50% in 2005) significantly increased from 2000 to 2005 (P=.03 and P=.01, respectively), compared with the proportion of cancer that was AIDS related and adjusting for age and sex.
  • Among cases involving AIDS, the proportion of non-Hodgkin lymphoma-associated deaths did not change statistically significantly between 2000 and 2005 (11% and 10% of deaths, respectively).
  • CONCLUSIONS: In this study, an increasing proportion of lethal non-AIDS-related cancers was demonstrated from 2000 to 2005; meanwhile, the proportion of lethal AIDS-related cancers remained stable among HIV-infected patients.
  • Thus, cancer prophylaxis, early diagnosis, and improved management should be included in the routine long-term follow-up of HIV-infected patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2009 Aug 1;49(3):481-2 [19586399.001]
  • [CommentIn] Clin Infect Dis. 2009 Mar 1;48(5):640-1 [19202628.001]
  • (PMID = 19202627.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Chêne G; Costagliola D; Jougla E; May T; Morlat P; Salmon D; Cacoub P; Rosenthal E; Bonnet F; Burty C; Lewden C; François M; Boileau J; Zouari H; Tourteau F; Bursacchi P; Delfraissy JF; Semaille C; Redecker S; Imbert Y; Rispal P; Allegre T; Riou J; Marquant M; Undreiner P; Abino J; Barel P; Greziller; Gosse; Lagier A; Bastide D; Schmit J; Decaux N; Chennebault J; Fialaire P; Abgueguen P; Loison J; Gaillat J; Legrand E; Dor J; Quinsat D; Lerousseau L; Chavaillon; Toquet-Maillet E; Sutton L; Genet P; Salord J; Raison G; Dubois D; Lierman Y; Bervar J; Castan B; Malbec D; Delassus J; Bakir R; Lepeu G; Pichancourt G; Theodourou-Touchais A; De La Blanchardiere OA; Evon P; Aubry Y; Giffo B; Bonnal F; Labarrere S; Amanieu M; Valet D; Faller J; Eglinger P; Duchene F; Humbert P; Dupond J; Estavoyer J; Hoen B; Roche C; Chirouze C; Faucher J; Oziol E; Saad A; Cabrol M; Gateau P; Seiberras S; Vidal C; Mazari A; Bentata M; Honore P; Bouchaud O; Bessin C; Jeantils V; Tassi S; Fain O; Dupon M; Morlat P; Beylot J; Lacoste D; Bonarek M; Bernard N; Bonnet F; Ragnaud J; Longy-Boursier M; Mercie P; Series C; Portal B; Terrier F; Rouveix E; Olivier C; Vaillant J; Moulias S; Hanslik T; Granier P; Colucci T; Mornet M; Aaron L; Guimard Y; Agbodjan J; Julien J; Fabre M; Garre M; Gouerou; Savary O; Nousbaum J; Granier H; Brousse P; Verdon R; Feret P; Guivarch; Sire S; Simonet P; Tempesta S; Vialatte B; Prudhomme L; Djossou F; Bichat S; Nacher M; Couppie P; Dellinger; Picard J; Sabbagh; Rogeaux O; Penalba C; Aubert C; Alba C; Galanaud P; Delavalle A; Boue F; Defuentes G; Pik J; Laurichesse H; Beytout J; Cormerais L; Fantin B; Uludag A; Mantz J; Cohen J; Kohser F; Plaisance N; Blaison G; Martinot M; Minozzi C; Ferreira C; Zeng F; Domart Y; Merrien D; Zylberait D; Devidas A; Turpauld I; Chevojon P; Bardet M; Jacquemard P; Sobel A; Jung C; Dumont C; Chousterman M; Housset B; Bassinet L; Schortgen F; Loste P; Antoniotti O; Nehme E; Granet P; Brunello; Portier H; Grappin M; Buisson M; Duong M; Braconnier C; Waldner-Combernoux A; Laine J; Brousse A; Cardon G; Visticot F; Vella M; Bonnevie F; Vanrenterghem; Soupison T; Gruat N; Roche J; Sicot; Saraux J; Lepretre A; El Hajj L; Frossard; Brung M; Lefebvre; Beguinot I; Schuhmacher H; Hirsch J; Reumont G; Saad; Galan; Estebe; Cabie A; Abel S; Quist D; Counillon E; Armero R; Del Giudice P; Gamblin V; Bouchard I; De Truchis P; Berthe H; Leclercq P; Brambilla C; Gineste E; Sarrot-Reynauld F; Jenny; Class J; Raynaud-Simon A; Alvarez F; Perre P; Aubry O; Suaud I; Courbes I; Batejat B; Dupont A; Lagarde P; David-Ouaknine F; Le Moigne E; Caumont B; Robin M; Hoel J; Doll J; Colardelle P; Roussin-Bretagne S; Greder A; Belan; Bedos J; Bruneel F; Thibous F; Lemeunier; Delfraissy J; Goujard C; Rannou M; Wind P; Monange B; Lamblin C; Cochonat K; Balquet M; De Ribes DC; Force G; Ceccaldi J; Marcos J; Hammou Y; Codaccioni X; Weinbreck P; Genet C; Debette-Gratien M; Geffray L; Le Mercier Y; Follet; Duvert B; Lacroix; Arnaud A; Selles Y; Levasseur F; Touraine J; Jeanblanc F; Trepo C; Benmakhlouf N; Lebouche B; Peyramond D; Boibieux A; Chidiac C; Delorme C; Carbonnel E; Baty V; Kisterman J; Roubert X; Granier F; Tremolières F; Billy C; Perronne V; Testaud J; Gastaut J; Drogoul M; Fabre G; Moreau J; Vandergheynst E; Bourliere M; Ruiz J; Philibert P; Gamby T; Petit N; Simon F; Fontaneau; Meissonnier P; Bayada J; Christian B; Armand A; Galzin M; Dumas D; De Witte S; Jobard J; Poncet A; Caillet B; Reynes J; De Boever CM; Siffert M; Bourgeois A; Villadoro A; Tramoni C; Faucherre V; Larrey D; Jonquet O; Landreau; Andre M; Winter C; Roge C; Beck-Wirth G; Drenou B; Benomar M; Ruel M; Chemlal K; Raffi F; Morineau-Le Houssine P; Le Bavec CG; Lemesre F; Masson B; Loison F; Razafimahery M; De Lacour JL; Dellamonica P; Mondain-Miton V; Cua E; Oran N; Valerio L; Rosenthal E; Fuzibet J; Tran A; Brocker P; Barrelier P; Vincent D; Mauboussin J; Barbuat C; Rouanet I; Jourdan N; Sotto A; Del Bucchia F; Jourdan J; Lapine M; Capdevielle P; Lacassin-Beller F; Droetto F; Diab G; Grihon F; Arsac P; Hocqueloux L; Levasseur M; Fourdilis M; Jarno P; Derouineau J; Morel P; Timsit F; Compagnucci A; Oksenhendler E; Gerard L; Delgado J; Sereni D; Lascoux-Combe C; Viard J; Dupont B; Maignan A; Bergmann J; Sellier P; Magnier J; Pialoux G; Godard V; Goetschel A; Lebrette M; Weiss L; Tisne-Dessus D; Leport C; Ecobichon J; Colasante U; Guillevin L; Salmon-Ceron D; Pietri M; Brunet A; Silbermann B; Blanche P; Schoen H; Valantin M; Hausfater P; Martinez V; Herson S; Simon A; Brancon C; Girard P; Begle A; Raguin G; Lupin C; Molina J; Ponscarme D; Garrait V; Cabotin P; Janier M; Spindler E; Yeni P; Gerbe J; Cabane J; Ziza J; Aerts J; Carlet J; Gilquin J; Auperin I; Misset B; Crof A; Piette J; Cacoub P; Turpin G; Varet B; Dupin N; Le Jeunne C; Aslangul E; Pol S; Poynard T; Lebray P; Carbonell N; Benlian P; Goujon M; Dhainaut J; Charpentier J; Andrieu J; Brunel M; Landgraf N; Bary M; Pouyanne; Meraud J; Riviere C; Aumaître H; Saada M; Cros H; Pellegrin J; Adjeoda R; Durieu I; Rousset H; Vital-Durand D; Lamaury I; Sow M; Hillion D; Masson H; Becq-Giraudon B; Le Moal G; Silvain C; Danne O; Blum L; Larzul J; Perfezou P; Rouger C; Novella J; Michelet C; Tattevin P; Arvieux C; Souala F; Delmont-Hanry M; Guyader D; Gandemer V; Camus C; Taverson; Lutz M; Climas M; Wemeau J; Gueit I; Suel P; Caron F; Mechali D; Khuong-Josses M; Etienne Y; Lucht F; Fresard A; Ronat V; Vergnon; Garcier; Deluca J; Randrianjohany A; Monnot H; Poubeau P; Andre H; Beuscart C; Aubry M; Hurbin E; Debord T; Rapp C; Bissuel F; Walter V; Ferret J; Bonnefoy M; Riche A; Marot J; Michau C; Bonnin E; Pasdeloup T; Chaby G; Grilliat E; Wurtz E; Loth F; Kitschke B; Line D; Gaud C; Sautron C; Cathebras P; Welker Y; Sandron D; Lang J; Fischer P; Pasquali J; Lalanne H; Chartier C; Berlin C; Andres E; Christmann D; Hansmann Y; Fraisse P; Bletry O; Zucman D; Majerholc C; Stern M; Couderc L; Petitou J; Truchetet F; Pouaha J; Romand P; Lafeuillade A; Lambry V; Bernard P; Adoue D; Duffaut M; Marchou B; Garipuy D; Cuzin L; Marchou B; Garipuy D; Cuzin L; Uzan M; Vinel J; Metivier S; Didier A; Rouquet R; Mouton Y; Yazdanpanah Y; Marysse F; Guery B; Faure K; Besnier J; Le Bret P; Nau P; Sigogneau H; Bressieux J; Libbrecht E; Rezzouk L; Collignon A; Ponceau B; Kyndt X; Vermersch-Langlin A; May T; Burty C; Lederlin P; Poinsignon Y; Creusat C; Richard C; Merle C; Essayan A; Vittecoq D; Bolliot C; Quignard; Patey O; Dellion S; Chossat I
  •  go-up   go-down


35. Stănescu L, Foarfă C, Georgescu AC, Georgescu I: Kaposi's sarcoma associated with AIDS. Rom J Morphol Embryol; 2007;48(2):181-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma associated with AIDS.
  • In the present KS is considerate an opportunistic neoplasm rather than a genuine cancer.
  • Four forms of Kaposi's sarcoma are recognized: classical, endemic (associated with AIDS), epidemic and iatrogenic (usually after transplant).
  • All these forms have the same histopathologic aspects and are associated with HHV.
  • The authors present a KS case associated with AIDS occurring at a patient in the childhood.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641807.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


36. Chitale AR: Cancer and AIDS. Indian J Pathol Microbiol; 2005 Apr;48(2):151-60
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and AIDS.
  • The occurrence of cancer as an AIDS defined disease is a subject that has received scant attention in the Indian medical establishments and lay public.
  • It is important to know that the concept of acquired immunodeficiency syndrome was ushered in with reports of rare forms of cancers in HIV infected subjects.
  • In the developed countries 34% of AIDS patients suffer from cancer, a cancer that is very aggressive, resistant to treatment and often fatal.
  • On the other hand, incidence of cancer in patients infected with HIV virus is only 3%-4% in the Indian population.
  • Nearly all patients with AIDS in India are victims of tuberculosis and opportunistic infections.
  • Among the various cancers reported in the Indian population Kaposi's sarcoma is very rare indeed.
  • AIDS associated malignant tumours tend to be more anaplastic and disseminate fairly early.
  • The object of this review is to increase awareness of the various aspects of cancer and AIDS.
  • There is an urgent need to improve gathering of epidemiological data and to direct research effort to explain a very strikingly low incidence of cancers in Indian subjects as compared to that in the West (prevalence of 4% versus 34% among HIV infected patients).
  • [MeSH-minor] Adult. Female. Humans. Incidence. India / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758653.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 64
  •  go-up   go-down


37. Aoki Y, Tosato G: Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol; 2007;312:309-26
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the advent of the HIV-1 pandemic, a close association between HIV-1 infection and the development of selected types of cancers has been brought to light.
  • The discovery of Kaposi sarcoma-associated herpesvirus (KSHV) has led to significant advances in uncovering the virological and molecular mechanisms involved in the pathogenesis of AIDS-related malignancies.
  • Extensive evidence indicates that HIV-1 trans-activating protein Tat plays an oncogenic role in the development of KSHV-associated neoplasms.
  • Comprehensive knowledge of the functions of Tat-1 together with the KSHV genes will contribute to a better understanding of the pathogenesis of virus-associated cancers and the interaction of viruses with their hosts.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089803.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Number-of-references] 122
  •  go-up   go-down


38. Maggiorella L, Wen B, Frascogna V, Opolon P, Bourhis J, Deutsch E: Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. Anticancer Res; 2005 Nov-Dec;25(6B):4357-62
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reports of dramatic improvement of AIDS-related cancers, such as primary central system lymphoma after radiation therapy as well as Kaposi's sarcoma, led to the recent discovery of the "non viral" antitumor activity of HIV protease inhibitors.
  • Thus, the antitumor effect of the latter combination is associated with the enhancement of radiation-induced apoptosis and inhibition of angiogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309240.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; O3J8G9O825 / Ritonavir
  •  go-up   go-down


39. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr; 2005 Jul 1;39(3):293-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cancer diagnosis in persons with AIDS.
  • The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies.
  • Similarly, the prognosis of cancer has also improved.
  • To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000.
  • Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis).
  • Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence.
  • The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types.
  • By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer.
  • For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types.
  • In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers.
  • We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS.
  • Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / mortality. Male. New York City / epidemiology. Prognosis. Registries. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / mortality. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980688.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


41. Beck F, Gautier A, Guilbert P, Peretti-Watel P: [Representations and attitudes toward cancer in the French general population]. Med Sci (Paris); 2009 May;25(5):529-33
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Representations and attitudes toward cancer in the French general population].
  • [Transliterated title] Représentations et attitudes du public vis-à-vis du cancer.
  • Cancer has become a major public health issue.
  • It is thus crucial to measure the general population's behaviours, opinions and perceptions about cancer and its associated risk factors.
  • Cancer is considered by a large majority to be the most serious disease, far before HIV/AIDS and cardiovascular diseases.
  • The carcinogenic risk that is associated to main risk factors, such as sun exposure, tobacco-smoking and alcohol use appears to be well-known.
  • Because self-exempting beliefs are still widespread within the general opinion, it is essential to continue public health information campaigns dedicated to cancer prevention, so as to induce better prevention practices within the general population and to reduce stigmatisation and isolation experienced by cancer patients.
  • If risk denial is not systematically a consequence of a lack of information, it is generally associated to a cognitive construction that gives coherence to behaviours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Sci (Paris). 2009 May;25(5):435-6 [19480816.001]
  • (PMID = 19480836.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  •  go-up   go-down


42. Cheung MC, Hicks LK, Leitch HA: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):E22-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is the second most common non-AIDS-defining malignancy among persons infected with HIV, and its incidence might be increasing in the current era of combination antiretroviral therapy (cART).
  • Antiretroviral therapy is commonly prescribed concomitantly with chemotherapy in the treatment of AIDS-related malignancies.
  • In particular, the potential for excessive vinca alkaloid-associated toxicity is significant, given the metabolism of drugs such as vinblastine by the 3A4 isoenzyme of the cytochrome P450 system and the inhibition of this isoenzyme by protease inhibitors.
  • We report 3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease. Lymphoma, AIDS-Related


43. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • The 75% survival time of patients who received treatment for their malignancy was longer than that of patients who received no treatment (18.3 vs 1.2 months; P<0.01).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561879.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


44. Bottler T, Kuttenberger J, Hardt N, Oehen HP, Baltensperger M: Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1218-20
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature.
  • Kaposi's sarcoma is a frequently seen AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614259.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 20
  •  go-up   go-down


45. Blanes M, Belinchón I, Merino E, Portilla J, Sánchez-Payá J, Betlloch I: [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection]. Actas Dermosifiliogr; 2010 Oct;101(8):702-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection].
  • The frequency of opportunistic infections and AIDS-related cancers has fallen, though new health problems have developed.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965013.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


46. Fujimuro M: [Kaposi's sarcoma-associated herpesvirus and mechanisms of oncogenesis]. Uirusu; 2006 Dec;56(2):209-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma-associated herpesvirus and mechanisms of oncogenesis].
  • Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8), is well known to be responsible for Kaposi's sarcoma, the most common AIDS-related cancer.
  • KSHV is also associated with the B cell malignancies primary effusion lymphoma and multicentric Castleman's disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446670.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / E2F Transcription Factors; 0 / Receptors, Notch; 0 / Viral Proteins; 0 / Wnt Proteins
  • [Number-of-references] 47
  •  go-up   go-down


47. Lavolé A, Epaud C, Rosencher L, Gounant V, Wislez M, Cadranel J: [Lung cancer in HIV-positive patients]. Rev Pneumol Clin; 2007 Jun;63(3):167-75
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in HIV-positive patients].
  • [Transliterated title] Le cancer broncho-pulmonaire chez les patients séropositifs pour le virus de l'immunodéficience humaine.
  • Since 1996, AIDS-related mortality has declined considerably with the introduction of tritherapy (HAART).
  • This decline in mortality has been associated with an increase in the proportion of deaths caused by cancers unrelated to AIDS, particularly lung cancer.
  • The risk of developing lung cancer is higher in the HIV-seropositive population than in the aged-matched general population, undoubtedly because of the high rate of smoking, particularly among drug abusers, but also because of other reasons which remain to be determined.
  • Mean age at the discovery of lung cancer in HIV+ patients is 45 years, and most are symptomatic.
  • Prospective clinical studies are needed to define a better management strategy for lung cancer in HIV-positive patients.
  • [MeSH-minor] Adenocarcinoma / complications. Age Factors. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Humans. Neoplasm Staging. Pneumonectomy. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675940.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


48. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


49. Bajaj BG, Murakami M, Robertson ES: Molecular biology of EBV in relationship to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:141-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of EBV in relationship to AIDS-associated oncogenesis.
  • Infection is nonsymptomatic in healthy individuals, but has been associated with a number of lymphoproliferative disorders when accompanied by immunosuppression.
  • In most malignant disorders associated with EBV, the virus replicates using one of these three latency programs.
  • The onset of the AIDS pandemic and the corresponding increase in individuals with acquired immunodeficiency resulted in a sharp increase in EBV-mediated AIDS-associated malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672040.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 139
  •  go-up   go-down


50. Hoffmann C, Horst HA, Weichenthal M, Hauschild A: Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution. Onkologie; 2005 Jan;28(1):35-7
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution.
  • BACKGROUND: Highly active antiretroviral therapy (HAART) has altered the course of most AIDS-related malignancies.


51. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst; 2009 Aug 19;101(16):1120-30
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of human papillomavirus-associated cancers among persons with AIDS.
  • BACKGROUND: Although risk of human papillomavirus (HPV)-associated cancers of the anus, cervix, oropharynx, penis, vagina, and vulva is increased among persons with AIDS, the etiologic role of immunosuppression is unclear and incidence trends for these cancers over time, particularly after the introduction of highly active antiretroviral therapy in 1996, are not well described.
  • METHODS: Data on 499 230 individuals diagnosed with AIDS from January 1, 1980, through December 31, 2004, were linked with cancer registries in 15 US regions.
  • Risk of in situ and invasive HPV-associated cancers, compared with that in the general population, was measured by use of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs).
  • We evaluated the relationship of immunosuppression with incidence during the period of 4-60 months after AIDS onset by use of CD4 T-cell counts measured at AIDS onset.
  • Incidence during the 4-60 months after AIDS onset was compared across three periods (1980-1989, 1990-1995, and 1996-2004).
  • RESULTS: Among persons with AIDS, we observed statistically significantly elevated risk of all HPV-associated in situ (SIRs ranged from 8.9, 95% CI = 8.0 to 9.9, for cervical cancer to 68.6, 95% CI = 59.7 to 78.4, for anal cancer among men) and invasive (SIRs ranged from 1.6, 95% CI = 1.2 to 2.1, for oropharyngeal cancer to 34.6, 95% CI = 30.8 to 38.8, for anal cancer among men) cancers.
  • During 1996-2004, low CD4 T-cell count was associated with statistically significantly increased risk of invasive anal cancer among men (relative risk [RR] per decline of 100 CD4 T cells per cubic millimeter = 1.34, 95% CI = 1.08 to 1.66, P = .006) and non-statistically significantly increased risk of in situ vagina or vulva cancer (RR = 1.52, 95% CI = 0.99 to 2.35, P = .055) and of invasive cervical cancer (RR = 1.32, 95% CI = 0.96 to 1.80, P = .077).
  • Among men, incidence (per 100 000 person-years) of in situ and invasive anal cancer was statistically significantly higher during 1996-2004 than during 1990-1995 (61% increase for in situ cancers, 18.3 cases vs 29.5 cases, respectively; RR = 1.71, 95% CI = 1.24 to 2.35, P < .001; and 104% increase for invasive cancers, 20.7 cases vs 42.3 cases, respectively; RR = 2.03, 95% CI = 1.54 to 2.68, P < .001).
  • Incidence of other cancers was stable over time.
  • CONCLUSIONS: Risk of HPV-associated cancers was elevated among persons with AIDS and increased with increasing immunosuppression.
  • The increasing incidence for anal cancer during 1996-2004 indicates that prolonged survival may be associated with increased risk of certain HPV-associated cancers.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HPV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2381-3 [17117025.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]
  • [Cites] Clin Infect Dis. 2007 Feb 1;44(3):441-6 [17205456.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer Treat Res. 2007;133:185-213 [17672042.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Lancet. 2001 May 5;357(9266):1411-2 [11356441.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):41-6 [12807944.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13 [15167289.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1343-9 [9358128.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):15-20 [9709296.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):256-64 [10454946.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1471-6 [15784870.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Sex Transm Dis. 2005 Nov;32(11):703-9 [16254546.001]
  • [Cites] Future Oncol. 2006 Feb;2(1):1-9 [16556066.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Aug 19;101(16):1103-5 [19648509.001]
  • (PMID = 19648510.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2728745
  •  go-up   go-down


52. Stebbing J, Duru O, Bower M: Non-AIDS-defining cancers. Curr Opin Infect Dis; 2009 Feb;22(1):7-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers.
  • PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs).
  • Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear.
  • RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532075.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


53. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. Gichuhi S, Irlam JJ: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev; 2007;(2):CD005643
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region.
  • SEARCH STRATEGY: Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the following electronic databases; Medline/PubMed, CENTRAL, AIDSearch, EMBASE, LILACS, African Healthline, Cochrane HIV/AIDS Specialised Register, and the Cochrane Cancer Network Specialised Register.
  • We searched the clinical trial register of the US National Institutes of Health, searched the international conference proceedings of AIDS and AIDS-related cancers, and contacted individual researchers, research organisations, and pharmaceutical companies that manufacture the drugs used as interventions.
  • HIV/AIDS research has not focused on treatment of this tumour.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;2:CD005643 [23450564.001]
  • (PMID = 17443606.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


55. Stebbing J, Wickenden C, Castellano L, Sita-Lumsden A, Nelson M, Jacob J, Naresh K, Mauri F, Bower M: No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer. AIDS; 2010 May 15;24(8):1221-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer.
  • AIDS-associated lung cancer has an increasing incidence, unaccounted for by smoking, and occurs consistently at a younger age than matched controls.
  • We investigated whether known and new cancer-associated polyomaviruses, including the newly identified Merkel cell virus, may play a role in its etiopathogenesis.
  • Although viruses target conserved pathways in cellular evolution, we are unable to suggest that the viruses studied here induce novel mechanisms of oncogenic dysregulation in AIDS-associated lung cancer.


56. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A, INSIGHT SMART and ESPRIT study groups: Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS; 2010 Mar 13;24(5):697-706
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.
  • OBJECTIVES: Among patients with HIV, the risk of death associated with different AIDS events has been quantified, but the risk of death associated with non-AIDS events has not been examined.
  • We compared the risk of all-cause mortality following AIDS versus serious non-AIDS (SNA) events in the Strategies for Management of Antiretroviral Therapy (SMART) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT).
  • METHODS: Cumulative mortality 6 months after AIDS and SNA events (cardiovascular, renal, hepatic disease, and malignancies) was estimated using the Kaplan-Meier method.
  • Cox models were used to estimate hazard ratios associated with AIDS and SNA events on the risk of death overall and by treatment group within study.
  • RESULTS: AIDS and SNA events occurred in 286 and 435 participants with 47 (16%) and 115 (26%) subsequent deaths, respectively.
  • Six-month cumulative mortality was 4.7% [95% confidence interval (CI) 2.8-8.0] after experiencing an AIDS event and 13.4% (95% CI 10.5-17.0) after experiencing an SNA event.
  • The adjusted hazard ratio for all-cause mortality for those who experienced AIDS versus those who did not was 4.9 (95% CI 3.6-6.8).
  • CONCLUSION: Among HIV-infected persons with higher CD4 cell counts, SNA events occur more frequently and are associated with a greater risk of death than AIDS events.
  • Future research should be aimed at comparing strategies to reduce morbidity and mortality associated with SNA events for HIV-infected persons.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Symptom Management .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1994 Apr 23;308(6936):1068-73 [7909698.001]
  • [Cites] HIV Med. 2007 Nov;8(8):547-54 [17944688.001]
  • [Cites] HIV Med. 2008 Feb;9(2):72-81 [18257770.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):179-87 [17075385.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70 [20700060.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] Curr HIV/AIDS Rep. 2009 May;6(2):83-92 [19358779.001]
  • [Cites] Clin Infect Dis. 2009 Sep 1;49(5):799-802 [19635024.001]
  • [Cites] Arch Intern Med. 2002 Nov 25;162(21):2405-10 [12437397.001]
  • [Cites] Acta Diabetol. 2004 Jun;41(2):77-83 [15224209.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9 [19430303.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2107-25 [7846414.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2022-9 [18984889.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1310-9 [19297565.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):379-86 [14615655.001]
  • [Cites] Curr Opin HIV AIDS. 2008 Mar;3(2):112-7 [19372951.001]
  • [Cites] HIV Clin Trials. 2008 May-Jun;9(3):177-85 [18547904.001]
  • [Cites] N Engl J Med. 2009 Oct 15;361(16):1548-59 [19828532.001]
  • [Cites] JAMA. 2008 Dec 17;300(23):2754-64 [19088353.001]
  • [Cites] AIDS. 2003 May 23;17(8):1179-93 [12819520.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1805-12 [16086718.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):289-99 [18765698.001]
  • [Cites] AIDS. 2008 Nov 30;22(18):2409-18 [19005264.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Clin Infect Dis. 2009 Apr 15;48(8):1138-51 [19275498.001]
  • [Cites] HIV Med. 2008 Apr;9(4):246-56 [18366449.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):590-8 [18645512.001]
  • [Cites] Int J Epidemiol. 2009 Dec;38(6):1624-33 [19820106.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Control Clin Trials. 2002 Apr;23(2):198-220 [11943448.001]
  • (PMID = 20177360.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01AI46362; United States / NIAID NIH HHS / AI / U01 AI068641-01; United States / NIAID NIH HHS / AI / U01 AI042170-12; United States / NIAID NIH HHS / AI / U01AI042170; United States / NIAID NIH HHS / AI / U01 AI046362-01; United States / NIAID NIH HHS / AI / U01 AI068641; United States / NIAID NIH HHS / AI / U01 AI046957-01; United States / NIAID NIH HHS / AI / U01 AI046957; United States / NIAID NIH HHS / AI / U01 AI046362; United States / NIAID NIH HHS / AI / U01AI068641; United Kingdom / Medical Research Council / / MC/ U122886352; United States / NIAID NIH HHS / AI / U01 AI042170; United States / NIAID NIH HHS / AI / U01AI46957
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS203665; NLM/ PMC2897168
  •  go-up   go-down


57. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol; 2009 Nov;83(22):11694-703
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stabilizing action of PRMT6 could allow Tat to persist within the cell and the extracellular environment and thereby enable functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]
  • [Cites] Retrovirology. 2009;6:1 [19128510.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1347-57 [16697675.001]
  • [Cites] Retrovirology. 2006;3:48 [16893449.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):401-13 [17088425.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):120-34 [17043108.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):214-8 [17215844.001]
  • [Cites] Retrovirology. 2006;3:93 [17176473.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):369-83 [17289585.001]
  • [Cites] J Virol. 2007 Apr;81(8):4226-34 [17267505.001]
  • [Cites] AIDS. 2007 Apr 23;21(7):795-805 [17415034.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):831-42 [17588518.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):843-52 [17588519.001]
  • [Cites] Curr HIV Res. 2007 Sep;5(5):473-83 [17896967.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):933-7 [17898714.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6106-18 [10545121.001]
  • [Cites] Mol Ther. 2000 Oct;2(4):404-14 [11020357.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28179-84 [11384967.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):7956-70 [11689688.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3537-43 [11724789.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3516-25 [12093752.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):209-15 [12115727.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Gene. 2004 Feb 4;326:1-11 [14729258.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] Cell. 2004 Jun 11;117(6):690-1 [15186770.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):559-71 [15327772.001]
  • [Cites] J Mol Biol. 1971 Dec 28;62(3):465-77 [5136579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10501-9 [7683681.001]
  • [Cites] Arch Virol. 1994;137(1-2):149-55 [7979988.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7844-50 [8631829.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):974-7 [8757599.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8145-8 [9079628.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] Cell. 1998 Feb 20;92(4):451-62 [9491887.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;61:65-131 [9752719.001]
  • [Cites] Virology. 1998 Dec 5;252(1):126-36 [9875323.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):353-60 [15525938.001]
  • [Cites] J Virol. 2005 Jan;79(1):124-31 [15596808.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e41 [15719057.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):263-72 [15866169.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):371-7 [16061726.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6402-11 [16272292.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1364-9 [16046164.001]
  • [Cites] Science. 2007 Oct 19;318(5849):444-7 [17947579.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3369-80 [18079182.001]
  • [Cites] Retrovirology. 2008;5:40 [18498648.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1433-9 [18418067.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1780(9):1062-9 [18573314.001]
  • [Cites] Retrovirology. 2008;5:63 [18620576.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3764-72 [16293633.001]
  • (PMID = 19726520.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 94ZLA3W45F / Arginine; EC 2.1.1.- / PRMT6 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  • [Other-IDs] NLM/ PMC2772670
  •  go-up   go-down


58. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • METHOD: Cancer registry data was reviewed for retrospective cases.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • These findings were not related to age, sex or type of lymphoma.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


59. Widney DP, Gui D, Popoviciu LM, Said JW, Breen EC, Huang X, Kitchen CM, Alcantar JM, Smith JB, Detels R, Martínez-Maza O: Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat; 2010;2010:164586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.
  • CXCL13/CXCR5 are expressed, and may play a role, in some non-AIDS-associated B cell tumors.
  • Objective. To determine if CXCL13/CXCR5 are associated with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed AIDS-NHL in the Multicenter AIDS Cohort Study and in controls.
  • The expression or function of CXCL13 and CXCR5 was examined on primary AIDS-NHL specimens or AIDS-NHL cell lines.
  • Results. Serum CXCL13 levels were significantly elevated in the AIDS-NHL group compared to controls.
  • All primary AIDS-NHL specimens showed CXCR5 expression and most also showed CXCL13 expression.
  • AIDS-NHL cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.
  • Conclusions. CXCL13/CXCR5 are expressed in AIDS-NHL and could potentially be involved in its biology.
  • CXCL13 may have potential as a biomarker for AIDS-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Aug;215(4):431-44 [18561120.001]
  • [Cites] J Neuroimmunol. 2008 Jul 31;198(1-2):106-12 [18539341.001]
  • [Cites] Blood. 2009 May 7;113(19):4604-13 [19228923.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1037-47 [8978608.001]
  • [Cites] Blood. 1997 Jul 15;90(2):520-5 [9226150.001]
  • [Cites] J Exp Med. 1998 Feb 16;187(4):655-60 [9463416.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):799-803 [9486651.001]
  • [Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]
  • [Cites] Breast Dis. 2004;20:137-43 [15687714.001]
  • [Cites] J Natl Cancer Inst. 1991 May 15;83(10):695-701 [2023270.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):576-81 [9207199.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Blood Rev. 1999 Sep;13(3):147-50 [10527266.001]
  • [Cites] Immunology. 2000 Feb;99(2):266-71 [10692046.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Immunol Rev. 2000 Aug;176:181-93 [11043777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):369-75 [11401467.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5028-37 [11431337.001]
  • [Cites] Blood. 2002 Jan 1;99(1):207-12 [11756173.001]
  • [Cites] Nature. 2002 Mar 7;416(6876):94-9 [11882900.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):1-8 [12101256.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] J Virol. 2003 Feb;77(3):2271-5 [12525664.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Blood. 2004 Jul 15;104(2):502-8 [15001469.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):489-96 [15349823.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]
  • [Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3316-25 [17652619.001]
  • [Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]
  • (PMID = 21490903.001).
  • [ISSN] 2090-1259
  • [Journal-full-title] AIDS research and treatment
  • [ISO-abbreviation] AIDS Res Treat
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA057152; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3065842
  •  go-up   go-down


60. An P, Winkler CA: Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet; 2010 Mar;26(3):119-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host genes associated with HIV/AIDS: advances in gene discovery.
  • Twenty-five years after the discovery of HIV as the cause of AIDS there is still no effective vaccine and no cure for this disease.
  • Multidisciplinary approaches integrating genetic epidemiology to systems biology will be required to fully understand virus-host interactions to effectively combat HIV/AIDS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Infect Dis. 2007 Apr 1;195(7):960-4 [17330785.001]
  • [Cites] J Virol. 2007 Apr;81(7):3477-86 [17251300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3354-9 [17360650.001]
  • [Cites] Retrovirology. 2007;4:20 [17374143.001]
  • [Cites] Virology. 2007 May 25;362(1):16-25 [17257639.001]
  • [Cites] AIDS. 2007 May 31;21(9):1091-101 [17502719.001]
  • [Cites] PLoS Genet. 2007 Apr 20;3(4):e63 [17447845.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 May;23(5):713-9 [17530998.001]
  • [Cites] PLoS Pathog. 2007 Jun;3(6):e88 [17590083.001]
  • [Cites] Science. 2007 Aug 17;317(5840):944-7 [17641165.001]
  • [Cites] Top HIV Med. 2007 Aug-Sep;15(4):134-6 [17720999.001]
  • [Cites] Immunity. 2007 Sep;27(3):406-16 [17892849.001]
  • [Cites] Science. 2008 Feb 15;319(5865):921-6 [18187620.001]
  • [Cites] PLoS Biol. 2008 Feb;6(2):e32 [18288889.001]
  • [Cites] Annu Rev Immunol. 2008;26:317-53 [18304004.001]
  • [Cites] PLoS One. 2008;3(4):e1954 [18414658.001]
  • [Cites] PLoS Pathog. 2008 Feb 8;4(2):e18 [18248091.001]
  • [Cites] J Infect Dis. 2008 Apr 15;197(8):1156-61 [18462163.001]
  • [Cites] J Med Virol. 2008 Jul;80(7):1133-41 [18461620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):263-71 [18391751.001]
  • [Cites] Cell Host Microbe. 2008 Jul 17;4(1):52-62 [18621010.001]
  • [Cites] PLoS One. 2008;3(7):e2747 [18648518.001]
  • [Cites] J Virol. 2008 Aug;82(16):8172-82 [18550667.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2626-35 [18684953.001]
  • [Cites] J Virol. 2008 Sep;82(17):8422-30 [18562530.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):864-7 [18684101.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1175-84 [18794856.001]
  • [Cites] Cell. 2008 Oct 3;135(1):49-60 [18854154.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):259-65 [18845960.001]
  • [Cites] PLoS One. 2008;3(11):e3636 [18982067.001]
  • [Cites] Cell Host Microbe. 2008 Nov 13;4(5):495-504 [18976975.001]
  • [Cites] Trends Microbiol. 2008 Dec;16(12):620-7 [18976921.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):19-28 [19050382.001]
  • [Cites] J Virol. 2009 Jan;83(1):295-303 [18945781.001]
  • [Cites] PLoS One. 2008;3(12):e3975 [19092998.001]
  • [Cites] PLoS One. 2008;3(12):e3907 [19107206.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):419-26 [19115949.001]
  • [Cites] Retrovirology. 2009;6:5 [19146679.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Virol. 2009 Mar;83(6):2460-8 [19109381.001]
  • [Cites] Bioorg Med Chem. 2009 Apr 15;17(8):3177-88 [19328002.001]
  • [Cites] N Engl J Med. 2009 Apr 23;360(17):1696-8 [19369660.001]
  • [Cites] J Infect Dis. 2009 Jun 1;199(11):1657-63 [19388851.001]
  • [Cites] Cell Host Microbe. 2009 May 8;5(5):408-10; author reply 418-9 [19454339.001]
  • [Cites] Cell Host Microbe. 2009 May 8;5(5):411-3; author reply 418-9 [19454340.001]
  • [Cites] Cell Host Microbe. 2009 May 8;5(5):413-5; author reply 418-9 [19454341.001]
  • [Cites] Cell Host Microbe. 2009 May 8;5(5):415-7; author reply 418-9 [19454342.001]
  • [Cites] PLoS Pathog. 2009 May;5(5):e1000437 [19478882.001]
  • [Cites] Mol Cell. 2009 Jun 26;34(6):696-709 [19560422.001]
  • [Cites] J Biol Chem. 2009 Jul 17;284(29):19463-73 [19460752.001]
  • [Cites] Curr HIV Res. 2009 Jul;7(4):384-9 [19601773.001]
  • [Cites] J Virol. 2009 Sep;83(18):9283-95 [19587052.001]
  • [Cites] J Virol. 2009 Sep;83(18):9474-85 [19587057.001]
  • [Cites] J Infect Dis. 2009 Oct 1;200(7):1054-8 [19698078.001]
  • [Cites] J Virol. 2009 Oct;83(19):10234-44 [19605475.001]
  • [Cites] J Infect Dis. 2009 Oct 15;200(8):1194-201 [19754311.001]
  • [Cites] Nat Med. 2009 Oct;15(10):1110-2 [19812560.001]
  • [Cites] Nat Med. 2009 Oct;15(10):1112-5 [19812561.001]
  • [Cites] Nat Med. 2009 Oct;15(10):1115-7 [19812562.001]
  • [Cites] Nat Med. 2009 Oct;15(10):1117-20 [19812563.001]
  • [Cites] AIDS. 2009 Oct 23;23(16):2091-100 [19710594.001]
  • [Cites] AIDS. 2010 Jan 16;24(2):195-204 [19996938.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Feb;53(2):260-5 [19745754.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2117-22 [11061652.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14467-72 [11121048.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1668-75 [11386265.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):782-95 [11694103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10002-7 [12114533.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] Genes Immun. 2003 Jun;4(4):245-50 [12761559.001]
  • [Cites] J Infect Dis. 2003 Jul 15;188(2):228-31 [12854077.001]
  • [Cites] Kidney Int Suppl. 2003 Feb;(83):S43-9 [12864874.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1056-60 [14564014.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Nov;24(11):971-5 [14687494.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):848-53 [14985764.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):565-74 [15167933.001]
  • [Cites] J Virol. 2004 Oct;78(20):11070-6 [15452227.001]
  • [Cites] Ann Intern Med. 1996 Apr 1;124(7):654-63 [8607594.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1856-62 [8791590.001]
  • [Cites] Science. 1997 Aug 15;277(5328):959-65 [9252328.001]
  • [Cites] Science. 1998 Jan 16;279(5349):389-93 [9430590.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):866-70 [9742978.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1907-11 [9836644.001]
  • [Cites] Science. 1999 Mar 12;283(5408):1748-52 [10073943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4581-5 [10200305.001]
  • [Cites] J Virol. 2004 Dec;78(24):14053-6 [15564514.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):159-63 [15609224.001]
  • [Cites] Science. 2005 Mar 4;307(5714):1434-40 [15637236.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):584-9 [15793370.001]
  • [Cites] AIDS. 2005 Jul 1;19(10):1015-24 [15958832.001]
  • [Cites] J Infect Dis. 2005 Sep 1;192(5):728-38 [16088822.001]
  • [Cites] J Virol. 2005 Sep;79(17):11513-6 [16103203.001]
  • [Cites] J Virol. 2005 Oct;79(20):12674-80 [16188970.001]
  • [Cites] Curr Biol. 2006 Jan 10;16(1):95-100 [16401428.001]
  • [Cites] World J Gastroenterol. 2005 Dec 28;11(48):7631-8 [16437690.001]
  • [Cites] J Virol. 2006 Mar;80(5):2463-71 [16474153.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):189-96 [16511411.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Feb;3(1):26-31 [16522256.001]
  • [Cites] J Virol. 2006 Jul;80(14):6757-63 [16809281.001]
  • [Cites] Curr Opin Microbiol. 2006 Aug;9(4):404-8 [16815734.001]
  • [Cites] J Virol. 2006 Sep;80(18):9259-69 [16940537.001]
  • [Cites] Retrovirology. 2006;3:54 [16925802.001]
  • [Cites] AIDS. 2006 Oct 3;20(15):1984-6 [16988524.001]
  • [Cites] Virology. 2006 Oct 10;354(1):15-27 [16887163.001]
  • [Cites] Retrovirology. 2006;3:79 [17087820.001]
  • [Cites] PLoS Genet. 2007 Jan 26;3(1):e19 [17257057.001]
  • (PMID = 20149939.001).
  • [ISSN] 0168-9525
  • [Journal-full-title] Trends in genetics : TIG
  • [ISO-abbreviation] Trends Genet.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA BC010297-13; United States / Intramural NIH HHS / / Z01 BC010297-10; United States / Intramural NIH HHS / / ZIA BC010297-12; United States / Intramural NIH HHS / / ZIA BC010297-14; United States / Intramural NIH HHS / / Z01 BC010297-11; United States / Intramural NIH HHS / / ZIA BC010297-15; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 107
  • [Other-IDs] NLM/ NIHMS486828; NLM/ PMC3792714
  •  go-up   go-down


61. Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS; 2008 Oct 18;22(16):2143-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
  • OBJECTIVE: To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.
  • We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM.
  • Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.
  • RESULTS: Three hundred five patients died due to a malignancy, 298 prior to the cutoff for this analysis (ADM: n = 110; nADM: n = 188).
  • In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality.
  • Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):855-63 [16107986.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):239-47 [17358029.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Blood. 2000 May 1;95(9):2860-8 [10779432.001]
  • [Cites] AIDS. 2000 May 5;14(7):771-80 [10839584.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1663-71 [12172088.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5 [12186222.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • [Cites] J Hepatol. 2005 Jun;42(6):799-805 [15973779.001]
  • (PMID = 18832878.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / 5U01AI046362-03; United States / NIAID NIH HHS / AI / U01 AI069907-02; United States / NIAID NIH HHS / AI / U01 AI046362; United States / NIAID NIH HHS / AI / 5U01AI042170-10; United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI042170
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS113887; NLM/ PMC2715844
  • [Investigator] Collins S; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjaer J; de Wolf F; Zaheri S; Gras L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JK; Geerlings SE; Godfried MH; Lange JM; van Leth FC; Lowe SH; van der Meer JT; Nellen FJ; Pogány K; van der Poll T; Reiss P; Ruys TA; Sankatsing SR; van Twillert G; van der Valk M; van Vonderen MG; Vrouenraets SM; van Vugt M; Wit FW; van Eeden A; ten Veen JH; van Dam PS; Roos JC; Brinkman K; Frissen PH; Weigel HM; Mulder JW; van Gorp EC; Meenhorst PL; Mairuhu AT; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen M; Richter C; van der Berg J; van Leusen R; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Koger EL; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; Miesen WM; Doedens R; Scholvinck EH; ten Kate RW; van Houte DP; Polee M; Kroon FP; van den Broek; van Dissel JT; Schippers EF; Schreij G; van de Geest S; Verbon A; Koopmans PP; Keuter M; Post F; van der Ven AJ; van der Ende ME; Gyssens IC; van der Feltz M; den Hollander JG; de Marie S; Nouwen JL; Rijnders BJ; de Vries TE; Juttmann JR; van de Heul C; van Kasteren ME; St Elisabeth SM; Bonten MJ; Borleffs JC; Ellerbroek PM; Hoepelman IM; Jaspers CA; Schouten I; Schurink CA; Blok WL; Tanis AA; Groeneveld PH; Salamon R; Beylot J; Dupon M; Le Bras M; Pellegrin JL; Ragnaud JM; Dabis F; Chêne G; Jacqmin-Gadda H; Thiébaut R; Lawson-Ayayi S; Lavignolle V; Balestre E; Blaizeau MJ; Decoin M; Formaggio AM; Delveaux S; Labarerre S; Uwamaliya B; Vimard E; Merchadou L; Palmer G; Touchard D; Dutoit D; Pereira F; Boulant B; Beylot J; Morlat P; Bernard N; Bonarek M; Bonnet F; Coadou B; Gelie P; Jaubert D; Nouts C; Lacoste D; Dupon M; Dutronc H; Cipriano G; Lafarie S; Chossat I; Lacut JY; Leng B; Pellegrin JL; Mercié P; Viallard JF; Faure I; Rispal P; Cipriano C; Tchamgoué S; Le Bras M; Djossou F; Malvy D; Pivetaud JP; Ragnaud JM; Chambon D; De La Taille C; Galperine T; Lafarie S; Neau D; Ochoa A; Beylot C; Doutre MS; Bezian JH; Moreau JF; Taupin JL; Conri C; Constans J; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Trimoulet P; Moreau F; Mestre C; Series C; Taytard A; Law M; Glenday K; Petoumenos K; Anderson J; Cortissos P; Mijch A; Watson K; Roth N; Nicolson J; Bloch M; Agrawal S; Franic T; Baker D; Vale R; Carr A; Cooper D; Lacey M; Hesse K; Chuah J; Lester D; Fankhauser W; Mallal S; Forsdyke C; Bulgannawar S; Calvo G; Torres F; Mateu S; Domingo P; Sambeat MA; Gatell J; Del Cacho E; Cadafalch J; Fuster M; Codina C; Sirera G; Vaqué A; Clumeck N; De Wit S; Gerard M; Kabeya K; Konopnicki D; Libois A; Payen MC; Poll B; Van Laethem Y; Neaton J; Bartsch G; El-Sadr WM; Krum E; Thompson G; Wentworth D; Luskin-Hawk R; Telzak E; El-Sadr WM; Abrams DI; Cohn D; Markowitz N; Arduino R; Mushatt D; Friedland G; Perez G; Tedaldi E; Fisher E; Gordin F; Crane RL; Sampson J; Baxter J; Kirk O; Olsen CH; Mocroft A; Phillips AN; Lundgren JD; Vetter N; Karpov I; Vassilenko A; Clumeck N; De Wit S; Poll B; Colebunders R; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Benfield T; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Zilmer K; Katlama C; Viard JP; Girard PM; Saint-Marc T; Vanhems P; Pradier C; Dabis F; Dietrich M; Manegold C; van Lunzen J; Stellbrink HJ; Staszewski S; Bieckel M; Goebel FD; Fätkenheuer C; Rockstroh J; Schmidt RE; Kosmidis J; Gargalianos P; Sambatakou H; Perdios J; Panos G; Filandras A; Banhegyi D; Mulcahy F; Yust I; Burke M; Turner D; Pollack S; Hassoun J; Sthoeger Z; Maayan S; Vella S; Chiesi A; Arici C; Pristerá R; Mazzotta F; Gabbuti A; Esposito R; Bedini A; Chirianni A; Montesarchio E; Vullo V; Santopadre P; Narciso P; Antinori A; Franci P; Zaccarelli M; Lazzarin A; Castagna A; Monforte Ad; Viksna L; Chaplinskas S; Hemmer R; Staub T; Reiss P; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Mansinho K; Maltez F; Duiculescu D; Babes V; Streinu-Cercel A; Vinogradova E; Rakhmanova A; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Sanchez-Conde M; García-Benayas T; Martin-Carbonero L; Soriano V; Clotet B; Jou A; Conejero J; Ruiz L; Tural C; Gatell JM; Miró JM; Zamora L; Blaxhult A; Karlsson A; Pehrson P; Ledergerber B; Weber R; Francioli P; Telenti A; Hirschel B; Soravia-Dunand V; Furrer H; Kravchenko E; Chentsova N; Fisher M; Brettle R; Barton S; Johnson AM; Mercey D; Murphy M; Johnson MA; Weber J; Scullard G; Morfeldt L; Thulin G; Sundström A; Akerlund B; Koppel K; Karlsson A; Flamholc L; Håkangård C; Monforte Ad; Ammassari A; Antinori A; Maggiolo F; Balotta C; Bonfanti P; Capobianchi M; Castagna A; Ceccherini-Silberstein F; Cozzi-Lepri A; Monforte Ad; De Luca A; Gervasoni C; Girardi E; Lo Caputo S; Murri R; Mussini C; Puoti M; Torti C; Moroni M; Carosi G; Cauda R; Chiodo F; Monforte Ad; Di Perri G; Galli M; Iardino R; Ippolito G; Lazzarin A; Mazzotta F; Panebianco R; Pastore G; Perno CF; Montroni M; Scalise G; Costantini A; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Maggiolo F; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Pizzigallo E; D'Alessandro M; Carnevale G; Zoncada A; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Pagano G; Cassola G; Alessandrini A; Piscopo R; Soscia F; Tacconi L; Orani A; Perini P; Tommasi D; Congedo P; Chiodera F; Castelli P; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Monforte Ad; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Gori A; Cagni S; Abrescia N; Chirianni A; Izzo CM; De Marco M; Viglietti R; Manzillo E; Ferrari C; Pizzaferri P; Filice G; Bruno R; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Andreoni M; Antinori A; Antonucci G; Narciso P; Tozzi V; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Lichtner M; Carletti F; Mura MC; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Raise E; Ebo F; Pellizzer G; Buonfrate D; Pradier C; Fontas E; Caissotti C; Dellamonica P; Bentz L; Bernard E; De Salvador-Guillouet F; Durant J; Mondain-Miton V; Perbost I; Prouvost-Keller B; Pugliese P; Rahelinirina V; Roger PM; Vandenbos F; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Egger M; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer HJ; Gorgievski M; Günthard H; Hirschel B; Kaiser L; Kind C; Klimkait T; Lauper U; Ledergerber B; Opravil M; Paccaud F; Pantaleo G; Perrin L; Piffaretti JC; Rickenbach M; Schmid CR; Schüpbach J; Speck R; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S
  •  go-up   go-down


62. Kotz D, Fidler J, West R: Factors associated with the use of aids to cessation in English smokers. Addiction; 2009 Aug;104(8):1403-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with the use of aids to cessation in English smokers.
  • AIMS: To assess factors associated with the use of smoking cessation aids among smokers trying to quit in a country where these aids are widely available and free or cheap to access.
  • Factors associated with an increased use of aids to cessation were female sex, older age, more cigarettes smoked per day and planning a quit attempt.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549267.001).
  • [ISSN] 1360-0443
  • [Journal-full-title] Addiction (Abingdon, England)
  • [ISO-abbreviation] Addiction
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


63. Strother RM, Gregory KM, Pastakia SD, Were P, Tenge C, Busakhala N, Jakait B, Schellhase EM, Rosmarin AG, Loehrer PJ: Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya. Oncology; 2010;78(1):5-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya.
  • OBJECTIVES: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program.
  • CONCLUSIONS: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting.
  • Gemcitabine as a single agent merits further investigation for AIDS-associated KS.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Kenya. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Failure. Treatment Outcome. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20215784.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; VBA protocol
  •  go-up   go-down


64. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS; 2006 Mar 21;20(5):741-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes.
  • Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified.
  • In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important.
  • The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU).
  • A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
  • OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cohort Studies. Disease Progression. Female. Follow-Up Studies. HIV Seropositivity. Hepatitis / mortality. Hepatitis / virology. Humans. Incidence. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / virology. Male. Multivariate Analysis. RNA, Viral / blood. Risk. Substance Abuse, Intravenous


65. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ: Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:69-127
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of KSHV in relation to AIDS-associated oncogenesis.
  • KSHV has been established as the causative agent of KS, PEL, and MCD, malignancies occurring more frequently in AIDS patients.
  • KSHV latent infection and lytic reactivation are characterized by distinct gene expression profiles, and both latency and lytic reactivation seem to be required for malignant progression.
  • As a sophisticated oncogenic virus, KSHV has evolved to possess a formidable repertoire of potent mechanisms that enable it to target and manipulate host cell pathways, leading to increased cell proliferation, increased cell survival, dysregulated angiogenesis, evasion of immunity, and malignant progression in the immunocompromised host.
  • The complex interplay between the two viruses dramatically elevates the risk for development of KSHV-induced malignancies, KS, PEL, and MCD.
  • In fact, clinically significant immune deficiency is not necessary for the induction of KSHV-related malignancy.
  • Because of variables such as lack of access to therapy noncompliance with prescribed treatment, failure to respond to treatment and the development of drug-resistant strains of HIV, KSHV-induced malignancies will continue to present as major health concerns.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):201-9 [10343071.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] J Virol. 1999 Aug;73(8):6953-63 [10400794.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S58-65 [10430220.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] J Gen Virol. 1999 Aug;80 ( Pt 8):2205-9 [10466820.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):827-40 [10499921.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1851-5 [10513642.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3349-54 [15271792.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] Cancer Invest. 2004;22(5):774-86 [15581058.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1310-8 [15471957.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3686-94 [15749907.001]
  • [Cites] Chest. 2005 Mar;127(3):762-7 [15764755.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] Blood. 2005 May 15;105(10):3987-94 [15665117.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26216-24 [15878864.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):949-55 [9714182.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2095-6 [9723403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] FASEB J. 2006 Jan;20(1):9-22 [16394262.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Virol. 2006 Feb;80(3):1385-92 [16415016.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2234-42 [16474131.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] J Virol. 2006 Mar;80(6):3062-70 [16501115.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] J Gen Virol. 2006 Apr;87(Pt 4):795-802 [16528027.001]
  • [Cites] J Virol. 2006 Apr;80(7):3445-58 [16537612.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3051-61 [16540654.001]
  • [Cites] J Virol. 2006 Apr;80(8):4068-78 [16571823.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Trends Microbiol. 2006 Apr;14(4):169-75 [16531046.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Wkly Epidemiol Rec. 2006 Jan 27;81(4):40 [16671237.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] J Virol. 2006 Jun;80(11):5371-82 [16699017.001]
  • [Cites] Virology. 2006 May 10;348(2):309-27 [16546233.001]
  • [Cites] Virology. 2006 Jun 20;350(1):192-205 [16616289.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1262-7 [16615115.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31863-7 [10542211.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • [Cites] Hum Immunol. 1999 Oct;60(10):921-7 [10566591.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900 [10580050.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] AIDS. 1998 Dec 24;12(18):2481-8 [9875587.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] Ann Biol Clin (Paris). 1999 Jan-Feb;57(1):19-28 [9920963.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Crit Rev Oncog. 1998;9(2):107-24 [9973245.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):243-51 [10068212.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Annu Rev Med. 1999;50:425-40 [10073287.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] J Hum Virol. 1999 Jan-Feb;2(1):19-32 [10200596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Leukemia. 1999 Apr;13 Suppl 1:S110-2 [10232382.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Blood. 2000 May 15;95(10):3032-43 [10807766.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1961-71 [10854219.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2179-83 [10854238.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):332-5 [10861641.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):43-7 [10884921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2049-58 [10900044.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Virol. 2000 Oct;74(20):9646-54 [11000237.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8254-63 [11027294.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2217-8 [11061672.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):25-36 [11082272.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 1;124(1):16-9 [11165317.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1864-9 [11160685.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2345-52 [11160738.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Mar;75(6):2866-78 [11222712.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):187-98 [11252894.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):156-63 [16014885.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] Trends Immunol. 2005 Sep;26(9):469-76 [16006187.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] J Virol. 2005 Oct;79(19):12173-84 [16160144.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2790-7 [15976177.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Oct;21(10):869-75 [16225414.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] J Virol. 2005 Nov;79(22):14457-64 [16254382.001]
  • [Cites] Virology. 2005 Dec 5;343(1):47-64 [16154170.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):193-8 [9653095.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] Adv Cancer Res. 2001;81:125-59 [11430594.001]
  • [Cites] Adv Cancer Res. 2001;81:161-200 [11430595.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Aug;75(15):7161-74 [11435597.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Gen Virol. 2001 Aug;82(Pt 8):1965-70 [11458004.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 25;1540(1):1-21 [11476890.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Virol. 2001 Sep;75(18):8660-73 [11507211.001]
  • [Cites] J Virol. 2001 Sep;75(18):8761-71 [11507221.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33805-11 [11448967.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3848-51 [11559722.001]
  • [Cites] J Virol. 2001 Nov;75(22):10933-40 [11602733.001]
  • [Cites] J Virol. 2001 Dec;75(23):11583-93 [11689640.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45979-87 [11590141.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3987-99 [11739795.001]
  • [Cites] J Pathol. 2001 Dec;195(5):586-92 [11745695.001]
  • [Cites] Biotechniques. 2001 Dec;31(6):1286, 1288, 1290, passim [11768657.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Gen Virol. 2002 Jan;83(Pt 1):179-88 [11752715.001]
  • [Cites] J Virol. 2002 Jan;76(2):802-16 [11752170.001]
  • [Cites] Blood. 2002 Jan 15;99(2):649-54 [11781250.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):23-9 [11786394.001]
  • [Cites] J Virol. 2002 Feb;76(4):1744-52 [11799169.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1226-34 [11801659.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d358-75 [11815281.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):791-5 [11857356.001]
  • [Cites] J Leukoc Biol. 2002 Mar;71(3):445-57 [11867682.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2634-43 [11884427.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2000 Jan;74(1):436-46 [10590133.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1151-7 [10666184.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] J Vasc Res. 2000 Jan-Feb;37(1):1-7 [10720880.001]
  • [Cites] J Virol. 2000 Apr;74(8):3659-67 [10729142.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7 [10733899.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1180-9 [10741750.001]
  • [Cites] J Clin Virol. 2000 May;16(3):203-13 [10738139.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] Mol Med. 1998 Jun;4(6):402-12 [10780883.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2002 Sep;76(17):8797-807 [12163600.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1940-9 [10837173.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):209-10 [10843538.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):404-11 [12226829.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):229-41 [12242155.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):975-83 [12352970.001]
  • [Cites] Virology. 2002 Sep 30;301(2):293-304 [12359431.001]
  • [Cites] J Virol. 2002 Nov;76(22):11491-504 [12388711.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2002 Dec;76(23):11880-8 [12414930.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Pathol. 2002 Dec;198(4):511-6 [12434421.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44765-71 [12235164.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Jan;77(1):592-9 [12477863.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] Annu Rev Med. 2003;54:285-303 [12525676.001]
  • [Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):1-3 [12556950.001]
  • [Cites] J Gen Virol. 2003 Feb;84(Pt 2):329-36 [12560564.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Mar;77(6):3878-81 [12610165.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] J Virol. 2003 Apr;77(7):4221-30 [12634379.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Gen Virol. 2003 May;84(Pt 5):1123-31 [12692277.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] J Virol. 2003 Jun;77(11):6188-96 [12743275.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):129-35 [12769790.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1485-91 [12771417.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2001 Apr;75(8):3948-59 [11264383.001]
  • [Cites] J Virol. 2001 Apr;75(8):4008-13 [11264393.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2374-80 [11290600.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):523-30 [11313983.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):800-11 [11314014.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516 [11313008.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):545-67 [11313011.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):245-57 [11325605.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jun;125(6):785-9 [11371231.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Dermatol Sci. 2001 Jul;26(3):182-93 [11390203.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Herpes. 2003 Dec;10(3):72-7 [14759339.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:237-48 [15033728.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] J Med Primatol. 2004 Feb;33(1):1-9 [15061726.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Blood. 2004 May 1;103(9):3465-73 [14726403.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Gen Virol. 2004 Jun;85(Pt 6):1347-61 [15166416.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27088-97 [15102829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Front Biosci. 1997 Mar 1;2:d126-46 [9159220.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5770-80 [15235582.001]
  • [Cites] Virus Genes. 2004 Oct;29(2):175-82 [15284477.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):387-96 [15288264.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] J Interferon Cytokine Res. 2004 Aug;24(8):439-54 [15320958.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2906-14 [15326101.001]
  • [Cites] J Virol. 2004 Sep;78(18):10187-92 [15331751.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2245-72 [15353285.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Virology. 2004 Oct 10;328(1):7-18 [15380353.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] J Virol. 2004 Oct;78(20):11108-20 [15452231.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12023-31 [11821384.001]
  • [Cites] J Virol. 2002 May;76(9):4390-400 [11932406.001]
  • [Cites] Biol Chem. 2002 Feb;383(2):255-61 [11934263.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5573-8 [11943871.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] DNA Cell Biol. 2002 Mar;21(3):151-62 [12015894.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1535-45 [12075072.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Virology. 2002 Jul 5;298(2):181-8 [12127781.001]
  • [Cites] J Cutan Pathol. 2002 Feb;29(2):72-8 [12150136.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):652-9 [12152166.001]
  • [Cites] Science. 1993 Feb 12;259(5097):971-4 [8438157.001]
  • [Cites] Medicine (Baltimore). 1993 Jul;72(4):245-61 [8341141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1291-6 [7692824.001]
  • [Cites] J Virol. 1994 Mar;68(3):1886-902 [8107249.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):191-6 [8062214.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2711-20 [7522639.001]
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1125-31 [7526889.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Res Virol. 1994 May-Aug;145(3-4):251-9 [7528440.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3582-92 [7897237.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1043-4 [7723505.001]
  • [Cites] Lancet. 1995 May 6;345(8958):1180 [7723569.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):596-9 [7637809.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):798; author reply 798-9 [7643891.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Gene Ther. 1994 May;1(3):208-16 [7584083.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] J Emerg Med. 1995 Sep-Oct;13(5):671-4 [8530789.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):450-5 [8618237.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):799-809 [8631301.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):542-9 [8627015.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):816-8 [8752276.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):1120-1 [8783733.001]
  • [Cites] AIDS. 1996 Feb;10(2):175-80 [8838705.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):285-91 [12856221.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Intervirology. 2003;46(3):141-9 [12867751.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9346-58 [12915550.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Sep;77(18):9758-68 [12941884.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] APMIS. 2003 Jul-Aug;111(7-8):698-714 [12974773.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] J Leukoc Biol. 2003 Nov;74(5):757-63 [12960240.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):514-23 [14724579.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):490-5 [9040590.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Lancet. 1997 Mar 15;349(9054):774-5 [9074581.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1193-7 [9129084.001]
  • [Cites] AIDS. 1997 May;11(6):713-21 [9143602.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):748-50 [9191012.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Lymphology. 1997 Jun;30(2):63-76 [9215976.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1656-9 [9287217.001]
  • [Cites] AIDS. 1997 Sep;11(11):1333-40 [9302442.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2826-9 [9326251.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] J Pathol. 1997 Jul;182(3):262-5 [9349227.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Virol. 1998 Jan;72(1):701-7 [9420276.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3537-42 [9520401.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] J Virol. 1998 Jul;72(7):5433-40 [9620998.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Virol. 2004 Nov;78(21):11926-38 [15479833.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2903-11 [15231571.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2736-8 [15238422.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] J Natl Cancer Inst. 1972 Dec;49(6):1509-26 [4647841.001]
  • [Cites] Am J Dermatopathol. 1981 Summer;3(2):111-4 [7270808.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] J Am Acad Dermatol. 1981 Oct;5(4):468-71 [7287964.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1439-44 [6272110.001]
  • [Cites] Ariz Med. 1981 Dec;38(12):902-4 [7332494.001]
  • [Cites] JAMA. 1986 Jul 4;256(1):20-1, 24-5 [3012133.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Cell. 1989 Aug 25;58(4):729-39 [2475256.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2448-57 [2342456.001]
  • [Cites] Cell. 1991 Sep 20;66(6):1071-4 [1833062.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 [1567395.001]
  • [Cites] Cancer Surv. 1991;10:5-22 [1821323.001]
  • [Cites] J Biol Chem. 1992 Dec 15;267(35):25589-96 [1460054.001]
  • [Cites] Gene Expr. 1992;2(4):329-37 [1472868.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):528-37 [8342600.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • (PMID = 17672038.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA124332-03; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NIDCR NIH HHS / DE / R01 DE017333-03; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NIDCR NIH HHS / DE / DE017333-02; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NIDCR NIH HHS / DE / R01 DE017333-02; United States / NCI NIH HHS / CA / R01 CA096512-05; United States / NCI NIH HHS / CA / R01 CA132637-02; United States / NIDCR NIH HHS / DE / DE017333-01; United States / NCI NIH HHS / CA / CA096512-02; United States / NIDCR NIH HHS / DE / DE017333-03; United States / NIDCR NIH HHS / DE / R01 DE017333; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NIDCR NIH HHS / DE / R01 DE017333-01; United States / NCI NIH HHS / CA / R01 CA132637; United States / NCI NIH HHS / CA / R01 CA132637-01A1; United States / NCI NIH HHS / CA / R01 CA124332-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 504
  • [Other-IDs] NLM/ NIHMS165766; NLM/ PMC2798888
  •  go-up   go-down


66. Bedoya F, Medveczky MM, Lund TC, Perl A, Horvath J, Jett SD, Medveczky PG: Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res; 2009 Nov;33(11):1499-504
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines.
  • One AIDS-associated lymphoma (EL) was further studied in detail as its mitochondrial genome consisted of tandem head-to-tail duplications.
  • Screening of several AIDS-associated lymphomas and established lymphoid cell lines also revealed the presence of mitochondrial genome concatemers consisting of interlinked monomer molecules.
  • Taken together, our results suggest that formation of mtDNA concatemers is associated with oncogenic transformation in lymphoid cells.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14453-8 [18796602.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] IUBMB Life. 2003 Apr-May;55(4-5):213-7 [12880201.001]
  • [Cites] Mol Genet Genomics. 2003 Jul;269(4):454-63 [12768414.001]
  • [Cites] Science. 2004 May 14;304(5673):981 [15143273.001]
  • [Cites] Biopolymers. 1970;9(3):373-9 [5417647.001]
  • [Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]
  • [Cites] J Virol. 1989 Sep;63(9):3601-11 [2547988.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Dec;38(12):2743-9 [7695256.001]
  • [Cites] Nucleic Acids Res. 1996 Oct 15;24(20):4084-91 [8918816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6 [9037025.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] Nucleic Acids Res. 1998 Feb 15;26(4):967-73 [9461455.001]
  • [Cites] Biochem Z. 1962;336:281-98 [14003030.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7 [16782042.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:363-74 [16869773.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] J Infect Dis. 2007 May 15;195(10):1419-25 [17436221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):9001-6 [17517629.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4331-5 [17671113.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Methods Mol Biol. 2007;372:153-66 [18314724.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):30-6 [18372105.001]
  • [Cites] Cancer Lett. 2008 Jul 18;266(1):21-9 [18374479.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):789-95 [11048730.001]
  • (PMID = 19362738.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111196-04; United States / NCI NIH HHS / CA / CA111196-02; United States / NCI NIH HHS / CA / R01CA111196; United States / NCI NIH HHS / CA / R01 CA111196-01A2; United States / NCI NIH HHS / CA / CA111196-03; United States / NCI NIH HHS / CA / R01 CA111196-03; United States / NCI NIH HHS / CA / CA111196-04; United States / NCI NIH HHS / CA / R01 CA111196; United States / NCI NIH HHS / CA / R01 CA111196-02; United States / NCI NIH HHS / CA / CA111196-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ NIHMS103972; NLM/ PMC2730422
  •  go-up   go-down


67. Mitsuyasu RT: Non--AIDS-defining malignancies in HIV. Top HIV Med; 2008 Oct-Nov;16(4):117-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non--AIDS-defining malignancies in HIV.
  • During the potent antiretroviral therapy era, the incidence of AIDS-defining cancers has decreased and the incidence of non--AIDS-defining cancers (NADCs) has increased, as has the proportion of mortality associated with NADC in HIV-infected patients.
  • The increase in NADCs is partly associated with increased longevity of the HIV-infected population, but it may also reflect consequences of increased immune activation and decreased immune surveillance as well as direct effects of HIV.
  • The NADCs appear to have earlier onset and worse prognosis in HIV-infected patients than in the general cancer population.
  • Among cancers that have increased in incidence are lung cancer, with its strong association with tobacco use, and skin cancers.
  • Much remains to be learned about risk, risk reduction, optimal treatment, and drug interactions in HIV-infected cancer patients.
  • This article summarizes a presentation on malignancies in HIV infection made by Ronald T.
  • Mitsuyasu, MD, at an International AIDS Society-USA Continuing Medical Education course in San Francisco in May 2008.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838745.001).
  • [ISSN] 1542-8826
  • [Journal-full-title] Topics in HIV medicine : a publication of the International AIDS Society, USA
  • [ISO-abbreviation] Top HIV Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


68. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA: Elevated risk of lung cancer among people with AIDS. AIDS; 2007 Jan 11;21(2):207-13
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated risk of lung cancer among people with AIDS.
  • BACKGROUND AND OBJECTIVES: Lung cancer is a common malignancy among people with AIDS (PWA).
  • Lung cancer risk was compared between PWA and the general population and its relationship with immunosuppression was assessed.
  • METHODS: Records on adolescent and adult PWA (N = 397 927) were linked with cancer registries in 11 US regions.
  • Cancer risk was assessed for the period 60 months before to 60 months after AIDS onset, with specific emphasis on the period 4-27 months after onset.
  • Observed incidence was compared with general population rates and rates from a lung cancer prediction model for smokers.
  • RESULTS: Compared with the general population, lung cancer risk among PWA was elevated overall [n = 1489 cases; standardized incidence ratio (SIR), 3.8; 95% confidence interval (CI), 3.6-4.1] and in the 4-27 months after AIDS (n = 393 cases; SIR, 2.9; 95% CI, 2.6-3.2).
  • In the 4-27 months after AIDS, risk was significantly elevated for all demographic subgroups, and was especially high among young PWA (SIRs for ages 15-29 years, 10.4; 30-39 years, 6.3; 40-49 years, 3.7).
  • Lung cancers generally presented at an advanced stage.
  • Risk was not associated with CD4 cell counts at AIDS (Ptrend = 0.36).
  • Under plausible smoking assumptions, observed incidence was significantly higher than predicted among 40-49 and 50-59-year-old men with AIDS (observed/predicted = 5.03 and 1.43, respectively) and 40-49-year-old women with AIDS (observed/predicted = 1.88), but not among older PWA.
  • CONCLUSION: Lung cancer risk was substantially elevated among PWA.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197812.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


69. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One; 2008 Jun 25;3(6):e2516
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.
  • LPS induces monocyte activation and trafficking into brain, which are key mechanisms in the pathogenesis of HIV-associated dementia (HAD).
  • To determine whether high LPS levels are associated with increased monocyte activation and HAD, we obtained peripheral blood samples from AIDS patients and examined plasma LPS by Limulus amebocyte lysate (LAL) assay, peripheral blood monocytes by FACS, and soluble markers of monocyte activation by ELISA.
  • High plasma LPS levels were associated with increased plasma sCD14 and LPS-binding protein (LBP) levels, and low endotoxin core antibody levels.
  • LPS levels were higher in HAD patients compared to control groups, and were associated with HAD independently of plasma viral load and CD4 counts.
  • LPS levels were higher in AIDS patients using intravenous heroin and/or ethanol, or with Hepatitis C virus (HCV) co-infection, compared to control groups.
  • These results suggest a role for elevated LPS levels in driving monocyte activation in AIDS, thereby contributing to the pathogenesis of HAD, and provide evidence that cofactors linked to substance abuse and HCV co-infection influence these processes.
  • [MeSH-major] AIDS Dementia Complex / immunology. Acquired Immunodeficiency Syndrome / metabolism. Lymphocyte Activation. Monocytes / immunology